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ABSTRACT 
We studied the glucose dependency of arginine vasopressin (AVP)-induced insulin 
and glucagon release from the perfused rat pancreas and the intracellular mechanism of 
cAMP/PKA-dependent enhancement of A VP-induced glucagon release. 
The study purpose was to investigate the glucose dependency of A VP-induced 
insulin, glucagon and somatostatin release from the perfused rat pancreas. AVP (30 or 300 
pmol/L) was tested in the presence of glucose concentrations of 0, 1.4, 5.5 (basal level), or 20 
mmol/L. The rates of insulin release at 0 and 1.4 mmol/L glucose were ~70-80% and -60-
70% less, respectively, than that at the baseline level. AVP (30 or 300 pmol/L) failed to 
change insulin release at 0 and 1.4 mmol/L glucose. At the basal glucose level, AVP (300 
pmol/L) induced a biphasic insulin release, a peak followed by a sustained phase. In 
addition, the combination of glucose (20 mmol/L) and AVP (300 pmol/L) induced a higher 
insulin peak and sustained phase than 20 mmol/L glucose alone. The rates of glucagon 
release at 0 and 1.4 mmol/L glucose were ~3- and ~2-fold more, respectively, than that at the 
baseline glucose level. At 0 and 1.4 mmol/L glucose, both 30 and 300 pmol/L AVP caused a 
higher glucagon peak and sustained phase than 0 and 1.4 mmol/L glucose alone. At the basal 
glucose level, AVP (30 or 300 pmol/L) induced a biphasic glucagon release, a peak followed 
by a sustained phase. The rate of glucagon release at 20 mmol/L glucose was -60-70% less 
than that at the baseline level. When AVP (300 pmol/L) was administered in 20 mmol/L 
glucose, it induced a transient glucagon peak, which was 2.4-fold of the baseline level. 
These findings suggested that AVP may increase insulin and glucagon release by a direct 
action on p- and a-cells, respectively. These increases are glucose-dependent; the higher the 
glucose concentration, the greater the enhancement of AVP induced insulin release. In 
contrast, the lower the glucose concentration, the greater the enhancement of A VP-induced 
glucagon release. AVP not only can enhance glucose-induced insulin release, but also can 
initiate insulin release, a-cells are much more sensitive to AVP than (3-cells in hormone 
release. Furthermore, our results confirmed the previous findings that hypoglycemia directly 
increases glucagon and decreases insulin release. 
X 
Increasing intracellular cAMP levels, by using forskolin or by preventing cAMP 
degradation with the phosphodiestrease inhibitor IBMX, enhanced A VP-induced glucagon 
release from the perfused rat pancreas and the clonal a-cells InRlG9. Pre-treatment with 
SQ-22536, an adenylyl cyclase inhibitor, abolished both the effect of forskolin on glucagon 
release and the enhancement effect on A VP-induced glucagon release. cAMP produced its 
effects through the stimulation of PKA, as a selective PKA inhibitor H-89 reduced the effect 
of forskolin on A VP-induced glucagon release and abolished the effect of forskolin on 
glucagon release. cAMP/PKA did not increase [Ca2+]; nor did it enhance A VP-induced 
[Ca2'], increase. Forskolin and IBMX enhanced A VP-induced glucagon release in Ca2+-
containing medium but not in C a2*-free medium. CaMK II plays a partial role in A VP-
induced glucagon release, since the selective inhibitor, KN93, partially blocked A VP-
induced glucagon release and forskolin/A VP-induced glucagon release. The fact that 
glucagon release was prolonged with forskolin treatment in the perfused rat pancreas and 
from InRlG9 cells led us to hypothesize that PKA promotes the mobilization of secretory 
granules from the reserve pool (RP) to the readily releasable pool (RRP). To test this 
hypothesis, InRlG9 cells were loaded with styryl dye FM1-43. The combination of AVP 
and forskolin induced more increase in fluorescence intensity (~ 4.8 fold of the control 
group) than AVP or forskolin alone (~ 2.1 and ~ 1.5 fold of the control group, respectively), 
which reflects an increase in the number of secretory granule membranes fused with the 
plasma membrane and in the size of the RRP. Secretory granules in the RP are thought to be 
reversibly connected to the actin-based cytoskeleton by synapsin I that have been proposed to 
play a major structural role in the assembly and maintenance of the RP secretory granules as 
well as a dynamic role in controlling secretory granules transitions from RP to RRP. 
Pretreatment with antisynapsin I antibody abolished the effect of forskolin/A VP-induced 
glucagon release but not glucagon release in the control, AVP, or forskolin groups. In 
addition, FM 1-43 loading experiments showed that synapsin I is involved in recruitment of 
secretory granules from RP to RRP. Our results suggested that cAMP, acting through PKA, 
increases the number of secretory granules in the RRP by mobilization of granules from the 
RP, an action mediated by synapsin I. 
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CHAPTER I. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is written in an alternative thesis format. It contains a general 
introduction, two research papers, a general discussion, and a list of references cited in the 
general introduction and discussion, and acknowledgments. The general introduction 
includes a research objective, background information and literature review. Chapter II, 
"Glucose-Dependency of Arginine Vasopressin-Induced Insulin and Glucagon Release from 
the Perfused Rat Pancreas ", accepted for publication in Metabolism, Chapter HI, "Cyclic 
AMP-Dependent Protein Kinase Enhances Arginine Vasopressin-Induced Glucagon Release 
by Increasing the Readily Releasable Pool: Involvement of Synapsin I", to be submitted to 
Journal of Biological Chemistry, and "Chapter IV, "General Discussion". 
This dissertation contains most of the experimental results obtained by the author 
during his graduate study under the supervision of his major professor. Dr. Walter H. Hsu. 
Research Objectives 
Glucagon is synthesized and secreted from the pancreatic a-cells in response to low 
blood glucose levels, and it plays a key role in maintaining glucose homeostasis. 
Understanding the regulation of glucagon release may contribute to a better control of type 2 
diabetes because excessive glucagon release in diabetic patients further aggravates the 
hyperglycemia caused by low insulin release (Unger and Oric, 1995). Glucagon can be 
inhibited or stimulated by a variety of nutrients and hormones. In our laboratory, we 
demonstrated the ability of AVP, a hormone found in the posterior pituitary gland as well as 
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in the pancreas, to stimulate glucagon (Yibchok-anun and Hsu, 1998) and insulin release 
(Lee et al., 1995) in rat pancreas, a-cell line InRlG9 and p-cell line RINmSF, respectively. 
AVP may regulate glucose metabolism by its direct glycogenolytic and gluconeogenic 
effects on the liver (Kirk et al., 1979), and by increasing insulin and glucagon release from 
the endocrine pancreas. The fact that AVP is present in the pancreas (Amico et al., 1988) 
suggests that AVP may exert a local control on the endocrine pancreas. 
The effects of AVP on the endocrine pancreas, insulin release in particular, are 
controversial. AVP ( 18.5-185 pmol/L) caused a concentration-dependent stimulation of 
glucagon release but failed to influence insulin release from isolated rat islets in medium 
containing 5.6 mmol/L glucose (Dunning et al., 1984a). In isolated mouse islets, AVP failed 
to change insulin release at < 7 mmol/L glucose but increased insulin at 10-30 mmol/L 
glucose (Gao et al., 1990; 1992). This implies that AVP is not a primary insulin 
secretagogue, but is an enhancer of glucose-induced insulin secretion. In the perfused rat 
pancreas, AVP (185 pmol/L) in 5.5 mmol/L glucose caused a small insulin release (Dunning 
et al., 1984b). In contradiction, AVP inhibited glucose-induced insulin release in rat islets 
(Khalaf and Taylor, 1988) and in hamster beta cell line (HIT) (Richardson et al., 1990). 
Since there are discrepancies in the effects of AVP on the endocrine pancreas, insulin release 
in particular, we investigated the direct effect of AVP (30 or 300 pmol/L) on insulin, 
glucagon and somatostatin release from the perfused rat pancreas in the presence of various 
glucose concentrations (0,1.4, 5.5, or 20 mmol/L). 
During hypoglycemic stress, glucagon release increases and insulin release decreases. 
Increased glucagon release is the main counterregulatory factor in the recovery of 
hypoglycemia (Gerich et al., 1979; Cryer PE, 1981). However, the mechanism underlying 
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hypoglycemia-induced glucagon release is uncertain. A number of studies suggest that the 
increase in release is due to activation of the autonomic nervous system (Havel and 
Taborsky, 1989; Havel and Valverde, 1996; Havel et al., 1996) while, others suggest that 
hypoglycemia directly stimulates glucagon release from the perfused rat pancreas and the 
perfused rat pancreatic islets (Weir et al., 1974; Oliver et al., 1976, respectively). Weir et al. 
(1974) showed that when perfusate was decreased from 5.5 mmol/L to 1.4 mmol/L glucose, 
glucagon was released in a biphasic pattern. While, Oliver et al. (1976) showed that low 
glucose concentrations of glucose per se failed to increase glucagon release, but arginine and 
epinephrine increased glucagon release at low glucose concentrations. We investigated the 
direct effects of various glucose concentrations (0, 1.4, 5.5, or 20 mmol/L) on insulin and 
glucagon release using the perfused rat pancreas. 
Ca2* plays a central role in secretagogue-induced glucagon secretion (Pipeleers et al., 
1985; Hii and Howell, 1987). Stimulation of pancreatic a-cells with secretagogues such as 
AVP results in a rise in [Ca2*], due to Ca2* release from endoplasmic reticulum and Ca2+ 
influx from the extracellular space (Yibchok-anun et al., 2000). A VP-induced glucagon 
release is largely mediated by a Ca2-dependent pathway (Yibchok-anun et al., 2000). Many 
effects of Ca2* are mediated through Ca2* -binding proteins such as calmodulin (CaM) 
(Colbran et al., 1989). The effects of Ca2* /CaM may be mediated by Ca2* /CaM-dependent 
protein kinase II (CaMK II) in neurons as well as in pancreatic (3-cells (Hanson and 
Schulman, 1992; Easom, 1999). cAMP enhances glucagon and insulin release from 
pancreatic a- and |3-cells, respectively, an action mediated by the activation of cAMP-
dependent protein kinase (PKA) (Wollheim et al., 1987; Gromada et al., 1997). We studied 
the interaction between the G protein-PLC pathway and PKA, in which cAMP/PKA 
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enhances A VP-induced glucagon release from the perfused rat pancreas and a-cell line 
InRlG9. The activation of specific effectors upstream and downstream from the Ca" signal 
remain largely unknown; for instance cAMP stimulates exocytosis even when [Ca2+]j is 
clamped at fixed concentrations and when the membrane potential is held too negative for 
Ca2" channels to open (Renstrom et al., 1997). Also elevation of intracellular cAMP 
concentration by forskolin, an adenylyl cyclase activator, evoked a PKA-dependent 
enhancement of exocytosis without increasing the [Ca2"]; (Renstrom et al., 1997). We 
investigated the mechanisms by which cAMP/PKA enhances A VP-induced glucagon release. 
The fact that glucagon release was prolonged with forskolin treatment in the perfused rat 
pancreas and from InRlG9 cells had led us to hypothesize that cAMP/ PKA promotes the 
mobilization of secretory granules from the reserve pool (RP) to the readily releasable pool 
(RRP). 
One possible mechanism for the recruitment of the secretory granules from RP is the 
release of granules from the actin-based cytoskeleton induced by phosphorylation of 
synapsin I (Greengard et al., 1993; Brodin et al., 1997; Benfenati et al., 1999; Hosaka et al., 
1999). Synapsin I has been proposed to play a major structural role in the assembly and 
maintenance of the RP of synaptic vesicles as well as a dynamic role in controlling synaptic 
vesicle transitions from the RP to the RRP (Greengard et al., 1993; Brodin et al., 1997; 
Benfenati et al., 1999). By analogy with neuronal cells, synapsin I in a-cells cells may 
function as a linker of glucagon secretory granules and the cytoskeletal network. Therefore, 
we hypothesized that synapsin I is involved in mobilization of glucagon granules from RP to 
RRP. A summary of possible interactions between PLC and PKA are shown in Fig. 1. 
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Forskolin 
te AMP 
Fig 1. Summary of possible interactions between Phospholipase C-|3 (PLC-(3) and cAMP-
dependent protein kinase A (PKA). PKA may enhance arginine vasopressin (AVP)-induced 
IP3 formation, which in turn further increases the Ca2+ release. PKA may enhance A VP-
induced glucagon release by enhancement of Ca2* influx or by mobilization of secretory 
granules from the reserve pool (RP) to the readily releasable pool (RRP). 
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In summary, the objectives of this study are: 1) to investigate the glucose-dependency 
of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas, 
and 2) to characterize the mechanisms by which cAMP/PKA enhances A VP-induced 
glucagon release and provide further details in the intracellular molecular components 
involved in this enhancement, particularly at the level of exocytosis. 
Background and Literature Review 
This section provides background information related to the studies that are presented 
in the dissertation: 1) The Pancreas; 2) Glucagon; 3) Events of exocytosis; 4) Regulation of 
hormone release by arginine vasopressin (AVP); 5) Role of cAMP-dependent protein kinase 
(PKA) in exocytosis; 6) The interaction between PKA and Phospholipase C (PLC); 7) 
Exocytotic proteins activation/deactivation and modulation of exocytosis; 8) Study of single 
cell exocytosis using fluorescent dye FM 1-43. 
The Pancreas 
The pancreas is a mixed gland with both exocrine and endocrine activities. It lies in 
the abdominopelvic cavity in the dorsal part of both the epigastric and the mesogastric 
abdominal segments, caudal to the liver. The pancreas is divided into four regions: lower 
duodenal (derived from the ventral primordium) and upper duodenal, gastric and splenic 
regions (derived from the dorsal primordium) (Elayat et al., 1995). The exocrine component 
is larger than the endocrine component and represents ~97-99% of the pancreatic volume 
(Hsu and Crump, 1989). It secretes digestive enzyme-rich fluid that enters into the proximal 
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part of the duodenum through one or two ducts. The digestive juice contains principally 
proteases, amylase and lipase the breakdown of proteins, carbohydrates and fats, 
respectively. The endocrine pancreas comprises the islets of Langerhans that are dispersed 
within the pancreas and represent -1-3% of the pancreatic volume (Hsu and Crump, 1989). 
The pancreatic islets contain at least four endocrine cells: P (or B) cells, a (or A) cells, 8 (or 
D) cells and F (or PP) cells, which secrete insulin, glucagon, somatostatin, and pancreatic 
polypeptide, respectively (Pelletier, 1977). The P cells form the central core and represent 
-75% of the islet cells, whereas a cells are generally located in the periphery and represent 
-20% of the islet cells (Karam, 1995). The Ô cells are located between a and P cells and 
represent -3-5% of the islet cells, while F cells are located near the a cells and represent 
<2% of the islet cells (Karam, 1995). 
The pancreatic islets are surrounded by an extensive, fenestrated capillary network 
that carries its hormones into the circulation. In addition to the pancreatic branches of the 
splenic artery, the cranial and caudal pancreaticoduodenal arteries are the major arteries 
supply blood to the pancreas, the former branching from the celiac artery, and the latter 
branching from the cranial mesenteric artery (Evans, 1993; Dyce et al., 1996). Venous blood 
returns to the portal vein. The pancreas is innervated by sympathetic and parasympathetic 
fibers (Hadley, 1992). The sympathetic fibers that innervate the pancreas arise from the 
celiac plexus and the parasympathetic fibers arise from the vagus nerve (Evans, 1993; Dyce 
et al., 1996). 
The islets of Langerhans play a central role in the hormonal control of fuel 
metabolism and glucose homeostasis. Maintenance of a normal plasma glucose 
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concentration during periods of food consumption and fasting requires a delicate balance 
between glucose production and utilization. Although control of the glucose homeostasis 
implicates many hormonal, neural, and autoregulatory factors, insulin and glucagon are the 
major determinants of this control. 
Glucagon 
Glucagon is a polypeptide hormone consisting of a single chain of 29 amino acids. 
Glucagon plays an important role in maintaining glucose homeostasis. It is secreted from the 
pancreatic a-cells in response to low blood glucose levels and stimulates hepatic glucose 
output by increasing glycogenolysis and gluconeogenesis, while at the same time inhibiting 
glycolysis (Burcelin et al., 1996). In addition to its metabolic actions in the liver, glucagon is 
also involved in the regulation of adipose, cardiac, renal, gastrointestinal, and pancreatic 
functions, including the potentiation of glucose-induced insulin release (Burcelin et al., 
1996). 
Glucagon can be inhibited or stimulated by a variety of nutrients and hormones. 
Glucose, somatostatin, insulin, free fatty acid, ketones, and y-aminobutyric acid are examples 
for nutrients and hormones that inhibit glucagon secretion (Ganong, 1995). a?-adrenergic 
agonists, (^-adrenergic agonists, acetylcholine, phosphodiestrase inhibitors, Cortisol, 
cholecystokinin, gastrin, secretin, and amino acids such as arginine, alanine, serine, glycine, 
cysteine and threonine are stimulators for glucagon secretion (Ganong, 1995). 
Understanding the regulation of glucagon release may contribute to better control of type 2 
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diabetes because excessive glucagon release in diabetic patients further aggravates the 
hyperglycemia caused by low insulin release (Unger and Oric, 1995). 
Events of Exocytosis 
Neurotransmitters and hormones are packaged in distinct vesicles, namely synaptic 
vesicles (SVs) and secretory granules or large dense core vesicles (LDVs), respectively. The 
key event in the SVs or LDVs cycle is exocytosis by membrane fusion. Membrane fusion 
occurs by a similar mechanism in organisms from yeast to man, and in organelles from the 
nuclear envelope to SVs (Bennett and Scheller, 1993,1994; Ferro-Novick and Jahn, 1994). 
Synaptic transmission requires a localized and a rapid signal that can be repeated at high 
frequencies and speeds (Sudhof, 1995). This is accomplished by three unique events in the 
cycle: a) before exocytosis, SVs are predocked at a specialized area called the active zone, b) 
the probability that a single docked SV will undergo exocytosis in response to Ca2" is low 
and can be modulated over a wide range, c) SVs quickly undergo endocytosis and recycle 
locally close to the site of exocytosis (Sudhof, 1995). 
Synaptic vesicle cycle 
Exocytosis has been extensively studied in neurons and thus has been used as a model 
to describe neuroendocrine cells. The synaptic vesicle (SV) cycle can be divided into 9 steps 
as shown in Fig. 2:1) Docking. The initial contact between presynaptic plasma membrane 
and SV membrane that occurs only at the active zone. The SVs that are filled with 
neurotransmitter dock at the active zone. 2) Priming. The maturation process of SVs that 
makes them ready for fusion in response to the Ca2 signal. 3) Fusion/ exocytosis. The 
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primed SVs go through fusion/ exocytosis in response to a Ca"" spike. Only one of many 
docked SVs fuses. 4) Endocytosis. After fusion/exocytosis, the empty SV membranes are 
rapidly internalized and become coated vesicle. 5) Translocation. Coated vesicles sheds 
their coats, acidify and translocate into the interior, becoming recycling SVs. 6) Endosome 
fusion. Recycling SVs fuse with early endosomes. 7) Budding. Budding from endosomes 
regenerates the SVs. 8) Neurotransmitter uptake. SVs are filled with neurotransmitters by 
the electrochemical gradient created by a proton pump (active transport). 9) Translocation. 
The filled SVs translocate back to the active zone by diffusion or cytoskeleton-based 
transport process. The SV cycle takes ~1 minute (Sudhof, 1995; Pyle et al., 2000), of which 
the exocytosis/fusion occurs in less than 1 ms, while endocytosis occurs in less than 5 s, and 
the other steps of the cycle occur in the remaining 55 s. 
Three functional pools of synaptic vesicles have been defined (Murthy and Stevens, 
1999). These are: a) the readily releasable pool (RRP) of synaptic vesicles: the most 
important vesicle pool for neurotransmitter release and constitutes vesicles that are 
immediately ready for release, b) the reserve pool (RP): when the RRP is depleted, further 
stimulation leads to recruitment of additional vesicles for exocytosis from RP. The RRP and 
the RP constitute the recycling pool, c) the resting pool: resting pool vesicles undergoes 
exocytosis only under extensive stimulation. 
SNAREs and SNARE-interacting protein 
Exocytosis requires proteins known as SNAREs, a set of three synaptic proteins, two from 
the plasma membrane (syntaxin and SNAP-25 (synaptosome-associated protein of 25 kDa) 
and one from synaptic vesicle protein (synaptobrevin, also known as VAMP, vesicle-
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associated membrane protein) (Sudhof, 1995; Mochida, 2000). During the priming step, 
SNAREs assemble a stable ternary complex (core complex) (Sudhof, 1995). The core 
complex forms the anchor for a cascade of protein-protein interactions required for 
exocytosis (Sudhof, 1995). SNAREs were originally identified as membrane receptors for 
NSF (N-ethylmaleimide-sensitive ATPase) and SNAPs (soluble NSF attachment proteins) 
and designated as SNAREs (SNAP receptor) (Sollner et al., 1993). NSF and SNAPs are 
soluble proteins that are essential for many intracellular vesicle fusion reactions (Mochida, 
2000). The discovery that botulinum and tetanus toxins block exocytosis by selectively 
proteolyzing the individual SNARE proteins provides evidence of the importance of these 
proteins in exocytosis (Schiavo et al., 1992; Sollner et al., 1993; Regazzi et al., 1995; Sadoul 
et al., 1995; Wheeler et al., 1996). The functions of SNAREs and SNARE-interacting 
proteins are summarized in Table 1. The protein-protein interaction is complicated (Sollner 
et al., 1993); nevertheless, SNAREs are essential for SV fusion machinery (Sollner et al., 
1993; Sudhof, 1995). SNARE-interacting proteins may regulate the efficiency and the 
strength of synaptic transmission underlying the synaptic plasticity (Sollner et al., 1993). 
Molecular events of exocytosis 
Sudhof (1995) proposed a model for the molecular events in exocytosis (Fig. 3). 
According to this model, when docking occurs, synaptobrevin (also known as vesicle-
associated membrane protein (VAMP)) and syntaxin are complexed to synaptophysin and 
munclS (nSecl) (synaptic vesicle proteins), respectively. These complexes dissociate during 
or after docking by unknown mechanisms. Syntaxin and SNAP-25 bind tightly to each other 
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Fig 2. The nine steps of the synaptic vesicle cycle in the presynaptic nerve terminal 
(Reprinted with permission from Nature, Sudhof TC, The synaptic vesicle cycle: a cascade of 
protein-protein interactions, 375:645-653,1995). 
Table I: SNARES and SNARE-associated proteins implicated in exocytosis. ** 
Classification Proteins Localization Speculated Functions 
SNARliS (SNARE core complex) Synaptobrevin/VAMP Synaptic vesicles 
Syntaxin Plasma membranes 
SNAP 25 Plasma membranes 
Fusion machinery 
SNARE core complex-interacting 
Proteins 
Syntaxin-interacting proteins 
NSF (an ATPase) 
a-SNAP 
Complex in 
Snapsin 
N-(and P/Q-type) 
Channels 
lomosyn 
Munc-18 
Syntaphilin 
Munc-13 
(Cytoplasm 
Cytoplasm 
Cytoplasm 
Synaptic vesicles 
Plasma membranes 
Cytoplasm and 
plasma membranes 
Cytoplasmic face of 
plasma membranes 
Plasma membranes 
Cytoplasmic face of 
plasma membranes 
SNAREs disassembly 
SNAREs disassembly 
Modulation of SNAREs assembly 
Modulation of SNAREs-synaptotagmin 
Interaction 
Synchronous NT release 
Transmission of voltage signal to SNARE 
Complexes 
Stimulation of SNAREs assembly 
Inhibition of SNAREs assembly 
Essential for synaptic vesicle fusion 
Inhibition of SNAREs assembly 
Enhancement of SNAREs assembly by DAG 
Promotion of synaptic vesicle trafficking by 
interaction with Doc2 
ui 
Table 1 (Continued) 
O TP-binding proteins and 
associated proteins 
Rab3A (a GTPase) Synaptic vesicles 
Rabphilin-3A 
Rim 
Synaptic vcsiclcs 
Active zone 
Limiting fusion machinery 
Generation of LTP 
Recruitment of synaptic vesicle to active zone 
Modulation of synaptic vesicle fusion 
Modulation of synaptic vesicle trafficking 
Promotion of synaptic vesicle fusion 
Ca2' -binding proteins Synaptotagmin I Synaptic vesicles Trigger of synaptic vesicle fusion 
containing two C2 domains 
Doc 2 Synaptic vesicles Promotion of synaptic vesicle trafficking by 
interaction with Munc-13 
Munc-13 
Rabphilin-3A 
Rim 
** Reprinted with permission from Elsevier Science, Mochida S: Protein-protein interactions in neurotransmitter release. 
Neurosci Res 36:175-182, 2000. 
15 
AH, CMMn iswntty comptai D, Dynemin KNSF HMUnclM FM, Plume membrane 
R3, Reb3A*3C HP, Rabphfln-3A S,«eflnr-SNAP S38.SNAP-2S SV. Synaptic vMide 
•VU SV membrane •A Syneplobiertn SyntSyntadn Syp, Syneptophytin »*t, SynapMagmin 
Fig 3. Protein-protein interaction cascade that mediate synaptic vesicle exo- and -
endocytosis (Reprinted with permission from Nature, Sudhof TC, The synaptic vesicle cycle: 
a cascade of protein-protein interactions, 375: 645-653, 1995). 
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and form a high affinity site for synaptobrevin to form the core complex with 1:1:1 
stoichiometry, which becomes sodium dodecyl sulfate resistant (Figs. 3 and 4). The core 
complex is composed of four parallel helices (four-helical bundle), with syntaxin contributing 
to its H3 domain, synaptobrevin contributing to its sole coiled-coil domain, and SNAP-25 
contributing to both of its coiled-coils (Fig. 5) (Lin and Scheller, 2000). Sixteen layers, 
denoted from -7 to +8 mediate the interactions between the four helices (Fig. 5). The 
interactions are primarily hydrophobic, with the exception of layer 0 in the middle of the 
bundle where syntaxin and SNAP-25 possess glutamine residues that interact ionically with 
the arginine residue from synaptobrevin (Lin and Scheller. 2000). These residues are 
conserved among SNARE homologous and are responsible for the recent classification into 
Q-SNAREs and R-SNAREs (Fasshauer et. al, 1998). SNARE complexes are formed by 
coiled-coil interactions immediately before fusion (Sutton et al., 1998). 
After the formation of the core complex, it serves as a receptor for SNAP and binds 
NSF where disassembly of the core complex by NSF ATPase activity occurs after the fusion 
of synaptic vesicles to the plasma membrane. Synaptotagmin then acts as a Ca2+ sensor in 
completing the fusion of secretory vesicles with the plasma membrane and followed by the 
release of their contents into the extracellular space. Subsequently, synaptotagmin acts as a 
nucleus for clathrin coat assembly by serving as an API receptor (clathrin assembly 
complex) in which clathrin and/or dynamin bind to AP2 and this will trigger endocytosis, 
which completes the exocytosis cycle. 
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SNAP-25 syntaxin 
Zippering 
Fusion 
Fig 4. Model pathway of SNARE-mediated synaptic vesicle membrane fusion. Syntaxin is 
initially unbound to VAMP or SNAP-25. Nucleation of the ternary complex is the initial 
event in membrane fusion. Calcium induces further zippering of the parallel helices, bringing 
the vesicle and plasma membranes into contact. This transient intermediate state either 
reverses rapidly or proceeds forward to membrane fusion, with the energy for fusion 
provided by complex formation (Reprinted with permission from Annu Rev Cell Dev Biol, 
Lin RC, Scheller RH, Mechanisms of synaptic vesicle exocytosis. 16:19-49,2000). 
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Syntaxin 
VAMP 
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Fig 5. Structure of the synaptic SNARE core complex, (a) The complex is made up of four 
parallel helices: syntaxin H3 domain, VAMP coiled-coil domain, SNAP-25 ammo-terminal 
helix, and SNAP-25 carboxy-terminal helix. Sixteen layers, from -7 to +8, mediate the 
interactions between the helices, (b) At layer 0, syntaxin and SNAP-25 contribute glutamine 
residues and VAMP contributes an arginine. Layer 0 possesses the greatest diameter of the 
layers and may be important in helix alignment or dissociation of the complex. Notice that 
because the coiled-coil domains of syntaxin and VAMP extend up to the transmembrane 
domains and align in a parallel fashion, the binding of syntaxin on the plasma membrane to 
VAMP on the vesicle would force the two membranes into apposition (Reprinted with 
permission from Annu Rev Cell Dev Biol, Lin RC, Scheller RH, Mechanisms of synaptic 
vesicle exocytosis. 16:19-49,2000). 
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Regulation of hormone release by arginine vasopressin (A VP) 
Biosynthesis and action of A VP 
A VP, a neurohypophysial nonapeptide hormone, is synthesized in supraoptic and 
paraventricular nuclei of the hypothalamus. After being synthesized, it is stored in 
neurosecretory granules and released from the posterior pituitary gland (Russell et al., 1990). 
A VP exerts a number of physiological roles in mammals; it plays a major role in regulating 
body fluid volume, osmolality and maintenance of blood pressure. In addition, A VP induces 
glycogeno lysis (Kirk et al., 1979), proliferation of the pituitary gland (Mcnichol et al., 1990) 
and vascular smooth muscle cells (Sperti and Colucci, 1991), vasoconstriction (Fox et al., 
1987), and release of catecholamine (Grazzini et al., 1996), ACTH (Antoni et al., 1984; 
Laszlo et al., 2001), insulin (Dunning et al., I984a,b; Chen et al., 1994) and glucagon 
(Yibchok-anun and Hsu, 1998; Yibchok-anun et al., 1999). 
A VP receptors 
The effects of A VP are mediated by two types of receptors, V, and V2 receptors 
(Guillon et al., 1980). The V, receptors have been further subclassified into Vta and V|b 
receptors because the binding properties of the V^ to various vasopressin agonists and 
antagonists differ from those of Vla receptors (Schwartz et al., 1991). V,a receptor is the 
most widespread subtype of A VP receptors and has been found in vascular smooth muscle, 
myometrium, bladder, adipocytes, hepatocytes, platelets, renal medullary interstitial cells, 
vasa recta in the renal microcirculation, epithelial cells in the renal cortical collecting duct, 
spleen, testis, and many CNS structures (Jackson, 1996). The Vlb receptor is primarily 
located in the adenohypophysis and has been detected in peripheral tissues (kidney, thymus, 
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heart, lung, spleen, uterus and breast) and some areas of the brain in the rat (Lolait et al., 
1995) as well as in the rat pancreas (Saito et al., 1995). V%y receptor has been 
pharmacologically characterized in the rat adrenal medulla (Grazzini et al., 1996), rabbit 
tracheal epithelium (Tamaoki et al., 1998) and rat pancreas (Lee et al., 1995). The V? 
receptor is found principally in cells of the renal collecting duct system. 
Signal transduction ofVi receptors 
A VP receptors are G protein-coupled receptors (Mouillac et al., 1995). The V, 
receptors are coupled to Gq to activate phospholipase C (Michell et al., 1979; Marc et al., 
1986), whereas the V, receptor is coupled to G$ to activate adenylyl cyclase, leading to 
generation of cAMP (Thibonnier, 1992). 
The signal transduction pathway of A VP has been investigated in various tissues, 
including smooth muscle, endothelium and endocrine cells (Spatz et al., 1994). V,y receptors 
mediate A VP-induced ACTH release (Antoni et al., 1984 and Schosser et al., 1994), insulin 
release in the perfused rat pancreas and clonal (3-cells (RINm5F) (Lee et al., 1995) and 
glucagon release in the perfused rat pancreas and clonal a-cells InRlG9 (Yibchok-anun and 
Hsu, 1998; Yibchok-anun et al., 1999). Generally, AVP binds to Vib receptors coupled to a 
pertussis toxin (PTX)-insensitive G-protein, probably Gq, which activates phospholipase C-(3 
(PLC-P) (Thibonnier et al., 1993). Activation of PLC-P catalyzes the hydrolysis of 
phospatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol and inositol 1,4,5-
trisphosphate (IP3). Diacylglycerol (DAG) activates Protein kinase C (PKC) and IP3 induces 
Ca2+ release from the endoplasmic reticulum, which leads to Ca2+ influx. Both Ca2+ release 
and Ca2+ influx contribute to A VP-induced insulin and glucagon release (Chen et al., 1994; 
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Yibchok-anun et al., 2000). A VP induces insulin (Chen et al., 1994) and glucagon (Yibchok-
anun et al., 2000) release through Ca2+-dependent and -independent pathways. 
Effect of glucose on A VP-induced insulin and glucagon release 
A VP may regulate glucose metabolism by its direct glycogenolytic and 
gluconeogenic effects on the liver (Kirk et al., 1979), and by increasing insulin and glucagon 
release from the endocrine pancreas. The fact that A VP is present in the pancreas (Amico et 
al., 1988) suggests that A VP may exert a local control on the endocrine pancreas. The 
effects of A VP on the endocrine pancreas, insulin release in particular, are controversial. 
AVP (18.5-185 pmol/L) caused a concentration-dependent stimulation of glucagon release 
but failed to influence insulin release from isolated rat islets in medium containing 5.6 
mmol/L glucose (Dunning et al., 1984a). In isolated mouse islets, AVP failed to change 
insulin release at < 7 mmol/L glucose but increased insulin at 10-30 mmol/L glucose (Gao et 
al., 1990; 1992). This implies that AVP is not a primary insulin secretagogue, but is an 
enhancer of glucose-induced insulin secretion. In the perfused rat pancreas, AVP (185 
pmol/L) in 5.5 mmol/L glucose caused a small insulin release (Dunning et al., 1984b). In 
contrary, AVP inhibited glucose-induced insulin release in rat islets (Khalaf and Taylor, 
1988) and in hamster beta cell line (HIT) (Richardson et al., 1990). Khalaf and Taylor 
(1988) showed that AVP (10 nmol/L) inhibited insulin release in the presence of 15 mmol/L 
glucose and was without effect in the presence of 5 mmol/L glucose. Richardson et al. 
(1990) showed that low doses of AVP (10 pmol/L) inhibited insulin release, while higher 
doses of AVP (100 pmol/L —100 nmol/L) increased insulin release. The inhibition of insulin 
release was not expected and was not explained. AVP (1-100 nmol/1) failed to stimulate 
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somatostatin release in the absence of extracellular glucose, however, AVP increased 
somatostatin release in the presence of glucose (3-30 mmol/L) (Gao et al., 1992). Since there 
are discrepancies in the effects of AVP on the endocrine pancreas, insulin release in 
particular, we investigated the direct effect of AVP (30 or 300 pmol/L) on insulin, glucagon 
and somatostatin release from the perfused rat pancreas in the presence of various glucose 
concentrations (0,1.4,5.5, or 20 mmol/L). We also investigated the direct effects of various 
glucose concentrations on insulin and glucagon release. 
Role of cAMP-dependent protein kinase (PKA) in exocytosis 
Changes in the intracellular cAMP concentration play an important role in the 
adjustment of cellular processes initiated by hormones, neurotransmitters and nutrients 
(Sutherland, 1972). The action of cAMP is mediated by the activation of cAMP-dependent 
protein kinase (PKA), which catalyzes the phosphorylation of a number of intracellular 
regulatory proteins including synapsin, rabphilin-3A, syntaxin and SNAP-25. In pancreatic 
P-cells, cAMP has been found to potentiate Ca2+ -dependent exocytosis (Wollheim et al., 
1987; Gillis and Misler, 1993). This is likely to be the mechanism by which glucagon 
(Rasmussen et al., 1990), glucose-dependent insulinotropic polypeptide (Gremlich et al., 
1995; Ding and Gromada, 1997) and glucagon-like peptide-1 (Thorens, 1995) enhance 
glucose-stimulated insulin release. The action of these hormones involves stimulation of 
adenylyl cyclase with resultant increase in intracellular cAMP concentration and activation 
of PKA. The ability of cAMP to stimulate insulin release can be prevented by Rp-cAMPS, a 
specific inhibitor of PKA (Wollheim et al., 1987). Experiments on permeabilized islets or p-
cells have suggested that the principal action of cAMP is exerted at a site distal to the 
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elevation of [Ca2+]i, and using capacitance measurements to determine exocytosis showed 
that this effect accounted for up to 80% of the exocytosis (Ammala et al., 1993). cAMP 
stimulates exocytosis even when [Ca2+]i is clamped at fixed concentrations and when the 
membrane potential is held too negative for voltage-dependent Ca2+ channels to open 
(Renstrom et al., 1997). Also elevation of intracellular cAMP concentration by forskolin, an 
adenylyl cyclase activator, evoked a PKA-dependent enhancement of exocytosis without 
increasing the [Ca2+]i (Renstrom et al., 1997). Using capacitance measurements as a single-
cell assay of exocytosis, cAMP -induced stimulation of exocytosis involves both increasing 
the release probability of secretory granules already in the RRP and by accelerating the 
refilling of this pool (Renstrom et al., 1997). 
The ability of cAMP to stimulate exocytosis is not confined to the pancreatic (3-cell, 
and it has been reported to enhance glucagon release from pancreatic a-cells (Gromada et al., 
1997). Forskolin evoked PKA-dependent potentiation of exocytosis by: a) enhancement of 
Ca2+ influx through L-type channels, which accounted for less than 30% of total stimulatory 
effect, b) acceleration of granules mobilization resulting in increase in the number of RRP, 
which accounted for 70% of the effect (Gromada et al., 1997). In addition, cAMP enhances 
exocytosis in rat pituitary somatotrophs (Cuttler et al., 1993) and melanotrophs (Skider et al., 
1990; Lee, 1996), bovine lactotrophs (Sikdar et al., 1990), dopamine-secreting PC -12 cells 
(Joseph and Kumar, 1995). In adrenal medulla, forskolin potentiates the secretory responses 
to nicotine, muscarine, bradykinin and histamine (Warashina, 1998). In these studies the 
stimulatory effect of cAMP/PKA was distal to further increase in [Ca2+]j. Skidar et al. (1998) 
investigated the putative modulation of unitary exocytosis events by cAMP in rat 
melanotrophs. They found an increase in the size of vesicles that fuse with plasma 
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membrane. Recently Machado et al. (2001) studied the role of cAMP/PKA on the late phase 
of exocytosis from single bovine chromaffin cells. They demonstrated that cAMP, probably 
acting on PKA, modulates the kinetics of exocytosis and increases the quantal size of 
secretory vesicles. Moreover, recruitment from RRP was depressed by inhibitors of 
cAMP/PKA and enhanced with their activator at Drosophila neuromuscular junctions 
(Kuromi and Kidokoro, 2000). The mobilization of vesicles was depressed with low cAMP, 
while it was enhanced with high cAMP (Kuromi and Kidokoro, 2000). 
The interaction between PKA and Phospholipase C (PLC) 
The heterotrimeric G proteins mediate a variety of cellular processes by coupling 
transmembrane receptors to different effector molecules, including adenylyl cyclase and 
phospholipase C-(3 (Simon et al., 1991; Neer, 1995). Activation of adenylyl cyclase results 
in the production of cAMP and activation of PKA. PLC catalyzes the hydrolysis of PIP? to 
generate DAG and IP3, leading to activation ofPKC and mobilization of [Ca2+]i, respectively. 
Interaction between the G protein-PLC pathway and PKA has been documented in numerous 
studies (Blackmore and Exton, 1986; Pittner and Fain, 1989a,b; Burgess et al., 1991; Rhee 
and Choi, 1992; Liu and Simon, 1996; Higashi et al., 1996; Rhee and Bae, 1997; Ali et al., 
1998; Dodge and Sanborn, 1998; Yue et al., 1998). Although it is generally agreed that PKA 
can inhibit G protein-activated PLC activity (Rhee and Choi, 1992; Liu and Simon, 1996; 
Rhee and Bae, 1997; Ali et al., 1998; Dodge and Sanborn, 1998; Yue et al., 1998), it can 
enhance the G protein-PLC pathway in some cases (Blackmore and Exton, 1986; Pittner and 
Fain, 1989a,b; Burgess et al., 1991; Higashi et al., 1996). 
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Inhibition of PLC via PKA 
The activation of PKA attenuates the PLC signaling pathway in a variety of cells. 
The proposed targets for phosphorylation includes cell surface receptors, G proteins, and 
PLC itself (Rhee and Bae, 1997). In human Jurkat T cells, activation of PKA results in an 
increase in phosphorylation of Ser1248 and a concomitant decrease in the tyrosine 
phosphorylation of PLCy-1, the latter of which might be responsible for the decreased PLC 
activity apparent in Jurkat cells treated with PKA-stimulating agonists (Rhee and Choi, 
1992). The interaction of PLC and PKA was studied in COS cells transfected with cDNAs 
encoding PLCP-2, G protein subunits, and PKA (Liu and Simon, 1996). Expression of the 
catalytic subunit of PKA specifically inhibited Gpy stimulation of PLCP-2 activity, without 
affecting Gq-induced activation. In addition, PKA directly phosphorylates serine residues of 
PLCP-2 both in vivo and in vitro (Liu and Simon, 1996). 
Phosphorylation ofPLCp-3 in response to a membrane-permeable cAMP analog 8-
(4-chlorophenylthio)-cAMP (cpt-cAMP) treatment in rat basophilic leukemia (RBL-2H3) 
cells expressing only PLCP-3 results in inhibition of G^-stimulated PLCp-3. PLCP-3 
activated by the G^-coupled formylmethionylleucylphenylalanine (fMLP) receptor but had 
no effect on platelet-activating factor (PAF)-stimulated PLCP-3 activity, presumably 
mediated by Gq (Ah et al., 1998). These studies led to the conclusions that phosphorylation 
of PLCP-2 and PLCP-3 by PKA could explain the inhibition of Gpv-stimulated PI turnover by 
cAMP (Liu and Simon, 1996; Ali et al., 1998). In a human myometrial cell line (PHM1-41) 
and in COS-M6 cells overexpressing the oxytocin receptor, preincubation with cpt-cAMP (a 
cell permeable PKA activating agent), forskolin or relax in inhibited oxytoc in-stimulated 
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phosphatidylinositide turnover in PHM1-41 cells. The inhibition was reversed by H-89, a 
relatively specific protein kinase A inhibitor (Dodge and Sanborn, 1998). In PHM1-41 and 
COS-M6 cells, phosphorylation of PLCP-3 Ser1105 by PKA results in a direct inhibition of 
Gq-stimulated PLCji-3 activity, which can at least partially explain the inhibitory effect of 
PKA on Gctq-coupled receptor-stimulated PI turnover observed in a variety of cells and 
tissues (Yue et al., 1998). 
Stimulation of PLC via PKA 
Although the activation of PKA attenuates the PLC signaling pathway in a variety of 
cells, PKA can stimulate the G protein-PLC pathway in some cases. Ethanol and AVP 
activate PLC in rat hepatocytes, generating IP3 and causing an increase in [Ca2+]j (Blackmore 
and Exton, 1986; Pittner and Fain, 1989a,b; Burgess et al., 1991; Higashi et al., 1996). The 
Ca2+ mobilization and IP3 accumulation induced by ethanol and AVP are potentiated by cpt-
cAMP (Higashi et al., 1996), although, agents that increase cAMP levels have no significant 
effects on basal inositol phosphate formation, but enhance A VP-induced inositol phosphate 
formation (Pittner and Fain, 1989a,b). Thus, at least two mechanisms might be involved: 
first, PKA potentiates the agonist-induced IP3 formation (Blackmore and Exton, 1986; Pittner 
and Fain, 1989a,b; Higashi et al., 1996), second, PKA potentiates the Ca2+ release from IP3-
sensitive Ca2+ stores in the cell by making the receptor more responsive to lower levels of IP3 
(Burgess et al., 1991). 
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Exocytotic proteins activation/deactivation and modulation of exocytosis 
Mechanism of granules mobilization 
The individual vesicle cycles and the transitions of vesicles between cycles are 
subject to extensive regulation, and Ca2+ mediates most of this regulation (Pyle et al., 2000). 
The control of synaptic vesicle cycle by increasing the number of vesicles in RRP through 
mobilization of vesicles from the RP (regulation of the releasable pools), or by increasing the 
number of docked vesicles that are ready for fusion (release probability of docked vesicles) is 
one way to regulate neurotransmitter release (Turner et al., 1999). The filling of the RRP, 
measured as recovery from depletion, is enhanced by elevated [Ca2+]j (Von Ruden and 
Neher, 1993). Protein Kinase C (PKC) (Gillis et al., 1996, Stevens and Sullivan, 1998;; 
Smith et al., 1998; Sudhof, 2000) and PKA (Renstrom et al., 1997) are also involved in the 
regulation of the size of RPP, which means the transfer of vesicles from the resting and 
reverse pools to reverse and RRP pool, respectively. 
The RRP is thought to correspond to the number of SVs docked morphologically to 
the presynaptic membrane that can be released (Rosenmund and Stevens, 1996; Dobrunz and 
Stevens, 1997). Morphological data have demonstrated that SVs in the RP are organized in 
clusters in which the SVs are reversibly linked to the actin-based cytoskeleton, by a family of 
abundant SVs -associated phosphoproteins, the synapsins (Landis et al., 1988; Bernstein and 
Bamburg, 1989; Hirokawa et al., 1989; Benfenati et al., 1993; Kuromi and Kidokoro, 1998). 
Synapsins are a family of phosphoproteins of SVs (Greengard, 1987). Three genes for 
synapsins have been described. The synapsin I gene, which produces alternatively spliced 
transcripts encoding synapsins la and lb, and the synapsin II gene encoding synapsins Ha and 
Lib (Sudhof et al., 1989). Sequence comparisons revealed that synapsins are composed of a 
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mosaic of domains. All synapsins share a short amino-terminal domain (A-domain), a linker 
sequence (B-domain) that is rich in short-chain amino acids (proline/alanine/ glycine/ serine), 
and a large central domain (C-domain) that comprises approximately one-half of the total 
synapsin sequences (Sudhof et al., 1989). After the C-domain, different combinations of 
domains are observed (the D-, E-, F-, and G-domains). At the very carboxyl terminus 
synapsins la and Da contain an additional short common domain of 50 residues (the E-
domain) (Sudhof et al., 1989). The E-domain is absent from synapsins lb and lib. Synapsin 
m, the newest member of the synapsins family was identified recently and is present in rat, 
mouse and human brains and predominantly expressed in neurons (Hosaka and Sudhof, 
1998; Kao et al., 1998). Synapsin HI is closely similar to synapsins la and 0a, with the 
highest similarity observed in the A-, C-, and E-domains (Hosaka and Sudhof, 1998). 
Therefore, synapsin HI is called synapsin Ilia. 
Granules mobilization due to synapsins activation 
The synapsins are known to associate with the regulation of neurotransmitter release, 
synaptic plasticity and synaptogenesis (Llinas et al. 1985; Han et al., 1991; Ferreira et al., 
1994; Rosahl et al., 1995). Synapsins have been proposed to play a major structural role in 
the assembly and maintenance of the RP of SVs as well as a dynamic role in controlling SVs 
transitions from the RP to the RRP (Greengard et al., 1993; Brodin et al., 1997; Benfenati et 
al., 1999). Synapsin I is associated with the regulation of neurotransmitter release, whereas 
synapsin II is known to be related not only to neurotransmitter release but also to 
synaptogenesis and synaptic plasticity (Ferreira et al., 1994; Rosahl et al., 1995). Synapsin I 
links SVs to the cytoskeleton, thus regulating the availability of SVs for exocytosis 
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(Benfenati et al., 1993, Ceccaldi et al., 1995). No study has yet examined whether synapsin 
II is associated with the SVs in the neurohypophysis, thus it remains unknown whether 
synapsin II plays a significant role in the regulation of SVs in the neurosecretory cells 
(Nomura et al., 2000). Recently, Sugiyama et al. (2000) showed that the number of 
releasable SVs were increased by synapsin II transfection into NG108-15 cells when 
compared to the control cells, which suggests that synapsin II may be involved in the 
regulation of SVs number in presynapsin-like structure NG108-15. However more studies 
are needed to elaborate the role of synapsin II in the regulation SVs. 
Several studies have suggested distinct roles for synapsin I and synapsin II during 
neuronal development. In cultured hippocampal neurons, synapsin I plays a major role in 
axonal elongation and branching (Chin et al., 1995), whereas synapsin II plays a major role 
in the initial elongation of undifferentiated processes (Ferreira et al., 1994, 1998). A recent 
study demonstrates that synapsin in has a role during development distinct from those of 
synapsins I and II (Ferreira et al., 2000). 
Protein kinases have an important role in mediating the release of SVs from the RP to 
RRP. Synapsin I and H are phosphorylated by both PKA and CaMK n (Nicol et al., 1997; 
Hosaka and Sudhof, 1999). Although PKA can phosphorylate synapsin I and II, the 
phosphorylation of synapsin I by CaMK II that is considerd to be the main way to mediate 
the release of synaptic vesicles (Turner et al., 1999). Therefore, the association of synapsin I 
with SVs has been characterized in detail. 
The introduction of the dephosphorylated form of synapsin I into the squid giant axon 
(Llinas et al., 1985; Lin et al., 1990), the gold fish Mauthner neuron (Hackett et al., 1990), or 
nerve terminals isolated from mammalian brain (Nichols et al., 1992) binds SVs and inhibits 
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neurotransmitter release. In contrast, introduction of synapsin I after its phosphorylation has 
no effect on neurotransmitter release (Greengard et al., 1993). The phosphorylation of 
synapsin I by CaMK II results in removal of the inhibition of the interaction between SVs 
and plasma membranes and thereby induces concomitant changes in Ca2+-dependent 
neurotransmitter release. (Matsumoto et al., 1990). These results indicate that the 
dephosphorylated form of synapsin I provides an inhibitory constraint for SVs exocytosis and 
that constraint is relieved upon phosphorylation of synapsin I (Greengard et al., 1993). 
Synapsin I is able to bind in vitro with various cytoskeletal proteins, including actin (Baines 
and Bennett, 1986; Bahler and Greengard, 1987). This indicates that synapsin I reversibly 
connects SVs to the actin-based cytoskeleton and that linkage is disrupted by 
phosphorylation (Benfenati et al., 1993, Ceccaldi et al., 1995; Hosaka et al., 1999). The 
binding of synapsin I to actin filaments leads to the formation of actin bundles in vitro and 
phosphorylation of synapsin I reduces actin binding and abolishes actin-bundling activity 
(Bahler and Greengard, 1987; Petrucci and Morrow, 1987). Moreover, microinjection of 
recombinant synapsin protein (domin E) inhibits exocytosis (Augustine et al., 1999; Ilrdi et 
al, 1999) and attenuates the supply of vesicles from the RP (Augustine et al., 1999). Thus, 
synapsin is involved in the release of SVs from the RP to refill the RRP pool thereby 
preventing its depletion by exocytosis, in addition to its role in vesicle fusion (Fig. 5) 
(Augustine et al., 1999). Synapsin I is phosphorylated at its N-terminus by CaMK II and 
PKA (Sudhof, 1995) and has been identified in adrenal medulla, adrenal chromaffin cells, rat 
islets, insulinoma cells including MIN6 and BTC3, and glucagon-secreting cells including a-
TC and InRlG9 cells (Matsumoto et al., 1999). The role of synapsin I in pancreatic P-cells is 
controversial. While some studies suggested that synapsin I is co-localizes with insulin 
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secretory granules (Matsumoto et al., 1999; Tabuchi et al., 2000), other studies suggested that 
synapsin I is not co-localized with insulin secretory granules, and thus may not play a role in 
granule mobilization (Krueger et al., 1999). 
In summary, under resting conditions, in which synapsin I is in the dephosphorylated 
state, most of the secretory vesicles are anchored to the cytoskeleton. Under neuroendocrine 
activity, in which synapsin I is in the phosphorylated state, the complex composed of SVs, 
synapsin I and actin dissociates and lead to liberation of more SVs from the RP to RRP 
(Greengard et al., 1993). Therefore, phosophorlation of synapsin I plays a key role in the 
regulation of the SVs and the transition from the RP to RRP. 
Phosphorylation of exocytotic proteins 
Several lines of evidence suggest that phosphorylation of exocytotic proteins plays a 
major role in modulating neuroendocrine release. However, the mechanisms by which 
protein kinases regulate neuroendocrine release are largely unknown. PKA, and CaMK II 
have been shown to phosphorylate a wide variety of vesicle proteins. Several protein kinase 
substrates have been characterized to function in the alteration of synaptic strength (synaptic 
plasticity) (see Sudhof, 1995 for review). 
This review will focus on the proteins that are known to be phosphorylated by PKA 
and CaMK II. In addition to synapsin I, PKA and CaMK II phophorylate other exocytotic 
proteins including: Rabphilin-3A, a synaptic vesicle protein, involved in both the docking 
and endocytosis of synaptic protein (Bums et al., 1998; Augustine et al., 1999). It is an 
important target of CaMK II and PKA (Lonart et al., 1998; Fykse et al., 1995), which is 
phosphorylated at the NHa-terminal (Bums et al., 1998). Rabphilin-3A binds to the vesicular 
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GTP-binding protein rab3A and maintains it in this state (Burns et al., 1998). Microinjection 
of recombinant rabphilin-3 A protein in squid giant synapses inhibits exocytosis and causes a 
relative accumulation of vesicles that may be awaiting docking (Bums et al., 1998; 
Augustine et al., 1999). Thus Raphilin-3A has multiple functions in the synaptic vesicle 
trafficking; it plays a role in membrane budding during endocytosis and also is involved in 
vesicle docking (Fig. 6) (Augustine et al., 1999). 
Syntaxin and SNAP-25 are plasma membrane proteins that bind tightly to each other 
and form a high-affinity site for synaptobrevin/VAMP to form a core complex (SNAREs) 
(Sudhof, 1995). Microinjection of clostridial toxin and several other reagents that prevent 
SNAREs from interacting inhibits neurotransmitter release (Augustine et al., 1999). Syntaxin 
and SNAP-25 are phosphorylated by CaMK II and PKA (Trudeau et al., 1998; Foster et al., 
1998). SNAP-25 has been shown to be expressed in pancreatic islets and in pancreatic a-
and p-cells (Sadoul et al., 1995). Botulinum neurotoxin (BoNT) A and E cleave SNAP-25 
(Sadoul et al., 1995), while BoNT CI cleaves syntaxin and leads to inhibition of Ca"-
dependent insulin release from permeabilized HIT cells (Wheeler et al., 1996; Land et al., 
1997). These findings suggest that SNAP-25 and syntaxin play a role in exocytosis of 
endocrine large-dense core granules. 
Study of single cell exocytosis using fluorescent dye FMI-43 
Several techniques have been developed to detect hormonal release. 
Radioimmunoassay is the mostly common used method to detect low concentrations of 
hormones such as insulin and glucagon. However, this method does not provide details with 
regards to the events of single cell exocytosis, endocytosis and synaptic vesicles recycling. 
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Fig 6. A model for the control of membrane trafficking reactions by presynaptic proteins 
(Reprinted with permission from J Physiol, Augustine GJ, Bums ME, DeBello WM, Hilfiker 
S, Morgan JR, Schweizer FE, Tokumaru H, Umayahara K, Proteins involved in synaptic 
vesicle trafficking. 520: 33-41, 1999). 
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Other methods have been developed to study single cell exocytosis including: 
electrophysiological measurements (cell membrane capacitance), amperometry and optical 
measurements using fluorescence imaging. Electrophysiological measurements of 
exocytosis using cell membrane capacitance measurements by the whole cell patch-clamp 
provides millisecond time resolution and measure the changes in the cell membrane area. 
This method has revealed three functionally distinct vesicle pools that give rise to multiple 
secretory phases (Murthy and Stevens, 1999). Amperometry is useful in monitoring 
secretion from single cells, even at the level of single exocytotic events, because it allows 
detection of attomole quantities with millisecond temporal resolution (Wightman et al., 1991; 
Chow et al., 1992). Amperometry has been applied to (3-cells either by using a ruthenium 
oxide/cyanoruthenate-coated microelectrode to directly detect insulin (Huang et al., 1995; 
Aspinwall et al., 1997) or by using a carbon fiber microelectrode to detect 5 -
hydroxytryptamine that had been allowed to accumulate in the secretory vesicles (Smith et 
al., 1995; Zhou and Misler, 1996). A limitation of amperometry is that a microelectrode is 
inherently a single-point sensor, meaning that measurements are made at one location on a 
cell with a detection area determined by the size of the electrode 
Recent advances in fluorescence imaging have resulted in new approaches to monitor 
exocytosis with a non-invasive method. Styryl dyes, which were originally developed as 
membrane potential sensors, become a useful tool in the study of exocytosis, endocytosis and 
synaptic vesicle recycling (Betz et al, 1996; Cochilla et al, 1999). This is due to their ability 
to reversibly stain membranes, their inability to penetrate membranes, and their fluorescence 
(Betz et al, 1996; Cochilla et al, 1999). FMI-43 is one of the most extensively used styryl 
dyes to study secretory activity (Cochilla et al, 1999). It is non-fluorescent in aqueous 
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solution, but became fluorescent and its quantum yield increases by ~ 350 times when 
incorporated into the plasma membrane (Betz et al, 1992). Therefore, the fluorescence 
intensity is proportional to the amount of membrane exposed to FM 1-43. Upon stimulation, 
exocytosis causes the vesicular membrane to fuse with the plasma membrane, and the dye 
binds to the exocytosing membrane resulting in an increase in the fluorescence intensity. 
The fluorescence intensity can be used as an index for RRP size (Sudhof, 2000). 
We used the fluorescent styryl dye FM 1-43 to investigate the mechanisms by which 
cAMP/PKA enhances A VP-induced glucagon release from clonal a-cells InRlG9 to 
determine if this enhancement is due to an increase in the number of secretory granules in 
RRP. 
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ABSTRACT 
The study purpose was to investigate the glucose dependency of arginine-vasopressin 
(AVP)-induced insulin, glucagon and somatostatin release from the perfused rat pancreas. 
A VP (30 or 300 pmol/L) was tested in the presence of glucose concentrations of 0, 1.4, 5.5 
(basal level), or 20 mmol/L. The rates of insulin release at 0 and 1.4 mmol/L glucose were 
-70-80% and -60-70% less, respectively, than that at the baseline level. A VP (30 or 300 
pmol/L) failed to change insulin release at 0 and 1.4 mmol/L glucose. At the basal glucose 
level, A VP (300 pmol/L) induced a biphasic insulin release, a peak followed by a sustained 
phase. In addition, the combination of glucose (20 mmol/L) and A VP (300 pmol/L) induced 
a higher insulin peak and sustained phase than 20 mmol/L glucose alone. The rates of 
glucagon release at 0 and 1.4 mmol/L glucose were ~3- and -2-fold more, respectively, than 
that at the baseline glucose level. At 0 and 1.4 mmol/L glucose, both 30 and 300 pmol/L 
A VP caused a higher glucagon peak and sustained phase than 0 and 1.4 mmol/L glucose 
alone. At the basal glucose level, A VP (30 or 300 pmol/L) induced a biphasic glucagon 
release, a peak followed by a sustained phase. The rate of glucagon release at 20 mmol/L 
glucose was -60-70% less than that at the baseline level. When A VP (300 pmol/L) was 
administered in 20 mmol/L glucose, it induced a transient glucagon peak, which was 2.4-fold 
of the baseline level. At all glucose concentrations tested, A VP (30 or 300 pmol/L) failed to 
change somatostatin release. These results suggested that 1 ) hypoglycemia directly increases 
glucagon and decreases insulin release, 2) A VP-induces insulin and glucagon release by a 
direct action on |3- and a-cells, respectively, 3) A VP- induces insulin and glucagon release in 
a glucose-dependent manner; the higher the glucose concentration, the greater the 
enhancement of A VP-induced insulin release. In contrast, the lower the glucose 
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concentration, the greater the enhancement of A VP-induced glucagon release, and 4) a-cells 
are more sensitive to A VP than (3-cells in hormone release. 
KEY WORDS 
Arginine vasopressin; Insulin; Glucagon; Somatostatin; Perfused pancreas; Glucose-
dependency. 
INTRODUCTION 
Arginine vasopressin (AVP), a neurohypophysial nonapeptide hormone, is 
synthesized in supraoptic and paraventricular nuclei of the hypothalamus. After being 
synthesized, it is stored in neurosecretory granules and released from the posterior pituitary 
gland.1 AVP is also found in extrapituitary tissues including adrenal gland2 and pancreas.3 
AVP exerts a number of physiological roles in mammals; it plays a major role in regulating 
body fluid volume, osmolality and maintenance of blood pressure. In addition, AVP induces 
glycogenosis4, proliferation of the pituitary gland5 and vascular smooth muscle cells6, 
vasoconstriction7, release of catecholamine9, insulin10'11 and glucagon 12-13 
AVP stimulates insulin and glucagon release via the activation of both phospholipase 
C (PLC)-dependent and -independent pathways.11-15 Via receptors mediate A VP-induced 
insulin release in the perfused rat pancreas and clonal /3-cells RJNm5F16, and glucagon 
release in the perfused rat pancreas and clonal a-cell line InRlG9.12-13 AVP induces insulin11 
and glucagon17 release through Ca2 -dependent and -independent pathways. For the Ca2+ -
dependent pathway, Gq protein activates phospholipase C, which catalyzes the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP?) to generate diacylglycerol and inositol 1,4,5-
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triphosphate (IP3). Diacylglycerol activates protein kinase C and IP3 induces Ca2-r release 
from the endoplasmic reticulum, which leads to Ca2" influx. Both Ca2+ release and Ca2"" 
influx contribute to A VP-induced insulin and glucagon release.11,17 
AVP may regulates glucose metabolism by its direct glycogenolytic and 
gluconeogenic effects on the liver4, and by modulating insulin and glucagon release from the 
endocrine pancreas. The fact that AVP is present in the pancreas3 suggests that AVP may 
exert a local control on the endocrine pancreas. The effects of AVP on the endocrine 
pancreas, insulin release in particular, are controversial. AVP caused a concentration-
dependent stimulation of glucagon release but failed to influence insulin release from isolated 
rat islets in medium containing 5.6 mmol/L glucose.18 In isolated mouse islets, AVP failed to 
change insulin release at < 7 mmol/L glucose.19-20 This implies that AVP is not a primary 
insulin secretagogue, but is an enhancer of glucose-induced insulin secretion. In the perfused 
rat pancreas, AVP in 5.5 mmol/L glucose caused a small insulin release.10 In contrast, AVP 
inhibited glucose-induced insulin release in rat islets21 and in clonal /3-cells HIT-T15.22 
AVP (1-100 nmol/1) failed to stimulate somatostatin release in the absence of extracellular 
glucose, however, AVP increased somatostatin release in the presence of glucose (3-30 
mmol/L).20 Since there are discrepancies in the effects of AVP on the endocrine pancreas, 
insulin release in particular, the present study was designed to study the direct effect of AVP 
(30 or 300 pmol/L) on insulin, glucagon and somatostatin release from the perfused rat 
pancreas in the presence of various glucose concentrations (0,1.4, 5.5, or 20 mmol/L). We 
also investigated the direct effects of various glucose concentrations on insulin and glucagon 
release. 
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MATERIALS AND METHODS 
Male Sprague-Dawley rats (350-450 g) were randomly used. The rats were 
anesthetized with pentobarbital sodium (60 mg/kg, intraperitoneally), and were maintained at 
37°C on a hot plate during the experiment. Pancreatic perfusion was performed as 
previously described.24 Briefly, after cannulation of the celiac artery, the rat pancreas was 
immediately perfused with Krebs-Ringer bicarbonate (KRB) solution supplemented with 20 
mmol/L HEPES, 5.5 mmol/L glucose, 1% dextran, and 0.2% bovine serum albumin as a 
basal medium. The KRB was maintained at pH 7.4 and continuously aerated with 95% O2 -
5% COi. The rats were euthanatized by the induction of pneumothorax immediately 
following the cannulation of the portal vein and the beginning of the flow. 
Experimental Design 
The first 20 minutes of perfusion was considered as an equilibration period. 
Subsequently, the effluent fluid was collected every minute from the cannula in the portal 
vein. The flow rate was set at 1 ml/minute. After a baseline period of 12 minutes, the 
medium containing glucose (0,1.4, 5.5, or 20 mmol/L) was administered for 30 minutes with 
or without AVP (30 or 300 pmol/L). This was followed by a washout period during which 
the basal medium was administered for 10 minutes. AVP of 30 and 300 pmol/L were chosen 
because AVP (3 pmol/L) caused a small increase in glucagon release and failed to increase 
insulin release. The effluent fluids were kept at 4°C and assayed within 6 hours for insulin, 
glucagon and somatostatin using radioimmunoassys as previously described.12'24'25 
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Test Agents 
AVP was purchased from Sigma Chemical Co. (St. Lous, MO), and dissolved in 
distilled water to make a stock solution (100 pmol/L). This solution was further diluted with 
KRB (basal medium) to attain appropriate concentrations. Glucagon and rat insulin 
standards were donated by Eli Lilly laboratories (Indianapolis, IN). Insulin antibody was 
donated by Dr. V. Leclercq-Meyer of the Free University of Brussels, Belgium. Glucagon 
antibody was donated by Dr. Joseph Dunbar of Wayne State University (Detroit, MI). 
Somatostatin antibody was donated by Dr. Y.N. Kenny Kwok of the University of British 
Columbia, Canada. l25I-glucagon was purchased from Linco Research (St. Charles, MO). 
Somatostatin standard was purchased from Sigma Chemical Co. (St. Lous, MO). 
Data Expression and Statistical Analysis 
The effluent concentrations of insulin, glucagon, and somatostatin were expressed as 
a percentage of the baseline level (mean of last 5 baseline values) in mean ± SE. The area 
under the curves (AUCs) for the different concentrations of glucose with or without AVP 
treatment period of 30 minutes was calculated using the Transforms and Regressions (Sigma 
Plot 5.0; SPSS Inc., Chicago, IL). One-way analysis of variance (ANOVA) was used to 
determine the effect of glucose concentrations on insulin and glucagon AUCs. Two-way 
ANOVA was used to determine the effect of AVP and glucose concentrations on insulin and 
glucagon AUCs. Individual mean comparisons were calculated using the F test. The 
significance level was set at P< .05. 
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RESULTS 
Effects of glucose on Insulin and Glucagon Release 
Insulin release remained constant in the basal glucose control group (5.5 mmol/L) 
throughout the perfusion period (Fig I A). In the absence of extracellular glucose or the 
presence of low glucose (1.4 mmol/L), insulin secretion was ~ 70-80% and ~ 60-70% less 
than that at the baseline level, respectively (Fig 1 A). By calculating the AUCs for 0 and 1.4 
mmol/L glucose groups and comparing them with those of basal glucose group, both 0 and 
1.4 mmol/L glucose had a significantly lower insulin release than the basal group. The 
higher concentration of glucose (20 mmol/L) induced a biphasic insulin release. The first 
transient insulin release peak was ~ 6-fold of the baseline level, followed by a sustained 
increase that was ~ 9-fold of the baseline level (Fig 2A). By calculating the AUCs for 20 
mmol/L glucose group and comparing them with those of the basal glucose group, 20 
mmol/L glucose significantly increased insulin release. 
Glucagon release remained constant in the basal glucose control group throughout the 
perfusion period (Fig IB). In the absence of extracellular glucose or the presence of 1.4 
mmol/L glucose, glucagon release was ~ 3- and - 2-fold higher than that at the baseline 
level, respectively (Fig IB). Relative to the level at the basal glucose concentration, 
glucagon release was significantly higher at the low glucose concentrations (0 and 1.4 
mmol/L). The higher concentration of glucose (20 mmol/L) significantly inhibited glucagon 
release, which was -60-70% less than that at the baseline level (Fig IB). Relative to the 
level at the basal glucose concentration, glucagon release was significantly lower at the high 
glucose concentrations (20 mmol/L). 
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Effects of AVP on Insulin Release 
At the basal glucose level AVP (30 pmol/L) failed to change insulin release, while 
AVP (300 pmol/L) induced a biphasic insulin release; a peak followed by a sustained phase 
(Fig 2C). By calculating the AUCs for the AVP (300 pmol/L) group and comparing them 
with those of the basal glucose group, AVP (300 pmol/L) significantly increased insulin 
release. Neither 30 nor 300 pmol/L AVP significantly increased insulin release at 0 and 1.4 
mmol/L glucose (Fig 2A and B). 
AVP (300 pmol/L) at 20 mmol/L glucose increased insulin release with a peak and a 
sustained phase of-15- and -25-fold of the baseline level, respectively (Fig 2D). By 
calculating the AUCs for AVP (300 pmol/L) in the 20 mmol/L glucose group and comparing 
them with those of the 20 mmol/L glucose alone group, AVP (300 pmol/L) in 20 mmol/L 
glucose significantly had a higher insulin release effect than did glucose alone. The insulin 
release induced by AVP (30 pmol/L) at 20 mmol/L glucose was not significantly different 
from that induced by 20 mmol/L glucose alone (Fig 2D). A summary of AVP (30 and 300 
pmol/L)-induced insulin release in various glucose concentrations is shown in Fig 4A, which 
demonstrates that the insulinotropic effect of AVP is glucose-dependent. 
Effects of A VP on Glucagon Release 
At the basal glucose level, both 30 and 300 pmol/L AVP increased glucagon release; 
a peak followed by a sustained phase (Fig 3C). AVP 30 pmol/L increased glucagon release 
with a peak and a sustained phase of -2-and -0.5-fold of the baseline level, respectively, 
whereas AVP 300 pmol/L caused a peak of -5- and a sustained phase of ~3-fold of the 
baseline level, respectively (Fig 3C). By calculating the AUCs for AVP (30 and 300 pmol/L) 
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groups and comparing them with those of basal glucose group, both 30 and 300 pmol/L AVP 
significantly increased glucagon release. 
In the absence of extracellular glucose, AVP (30 pmol/L) increased glucagon release 
with a peak and a sustained phase of ~5- and ~ 10-fold of the baseline level, respectively, 
whereas AVP (300 pmol/L) caused a peak and a sustained phase of ~11- and ~35-fold of the 
baseline level, respectively (Fig 3 A and B). In the presence of 1.4 mmol/L, AVP (30 
pmol/L) increased glucagon release with a peak and a sustained increase of ~5- and ~7-fold 
of the baseline level, respectively, whereas AVP (300 pmol/L) caused a peak and a sustained 
phase of 5 and <21-fold of the baseline level, respectively (Fig 3 A and B). By calculating 
the AUCs for AVP (30 and 300 pmol/L) in 0 or 1.4 mmol/L glucose groups and comparing 
them with those of the 0 or 1.4 mmol/L glucose groups, both 30 and 300 pmol/L AVP 
significantly had higher glucagon release than 0 or 1.4 mmol/L glucose alone. 
The higher concentration of glucose (20 mmol/L) significantly inhibited glucagon 
release, under this conditions, AVP (30 pmol/L) failed to change glucagon release (Fig 3D). 
However, AVP (300 pmol/L) at 20 mmol/L glucose induced a significant glucagon release 
for 5 minutes when compared to the glucose alone group (Fig 3D). A summary of AVP (30 
and 300 pmol/L)-induced glucagon release in various glucose concentrations is shown in Fig 
4B, which demonstrates that the glucagonotropic effect of AVP is glucose-dependent. 
Effects of A VP on Somatostatin Release 
Neither the various concentrations of glucose (0, 1.4, 5.5, or 20 mmol/L) alone, nor 
AVP (30 or 300 pmol/L) in glucose (0,1.4, 5.5, or 20 mmol/L) changed somatostatin release 
from the perfused pancreas (data not shown). 
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DISCUSSION 
In the present study, AVP evoked both the release of insulin and glucagon from the 
perfused rat pancreas in a glucose concentration-dependent manner. AVP (30 and 300 
pmol/L) failed to induce insulin release at glucose concentrations of 0 and 1.4 mmol/L. 
However, in the presence of basal glucose level (5.5 mmol/L), AVP (300 pmol/L) increased 
insulin release, and it induced a greater increase in insulin release at 20 mmol/L glucose. 
These findings suggested that the higher the glucose concentration, the greater the 
enhancement of A VP-induced insulin release. In mouse islets, AVP (100 nmol/L) in the 
presence of 0, 3, or 7 mmol/L glucose failed to induce insulin release, while at higher glucose 
concentrations (10-30 mmol/L), AVP (1-100 nmol/L) enhanced glucose-induced insulin 
release.20 These authors concluded that AVP is not an initiator of insulin release but only 
enhanced glucose-induced insulin release. In contrast, our study demonstrated that lower 
concentration of AVP (30 pmol/L) not only enhanced glucose-induced insulin release, but 
also initiated insulin release at the basal level of glucose. The discrepancy between these 
findings may be attributed to the use of two different preparations. In our study we used the 
perfused pancreas, which requires a much less invasive procedure than the use of isolated 
islets, in which the pancreas remains intact. In addition, Gao et al.20 preincubated the mouse 
islets for 60 minutes to permit the recovery from the isolation procedure. This period of 
incubation may not be sufficient, because a minimum incubation of24-48 hours is essential 
for receptors recovery.26 This might also explain why in the mouse islets high concentrations 
of AVP were used to demonstrate AVP's effects and why AVP failed to initiate insulin 
release. 
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We also investigated the effects of different glucose concentrations on insulin and 
glucagon release from the perfused rat pancreas. The rate of insulin release in the presence 
of 0 and 1.4 mmol/L glucose was ~70-80% and -60-70% less, respectively, than the baseline 
level. The basal glucose concentration (5.5 mmol/L), maintained a constant level of insulin 
through out the perfusion period, whereas a higher glucose concentration (20 mmol/L) 
induced a biphasic release pattern; a transient peak followed by a sustained phase with a 
greater magnitude. Similar findings have been reported in the perfused rat pancreata27,28 and 
human islets29,30. On the other hand, the rates of glucagon release in the presence of 0 and 
1.4 mmol/L glucose was ~3- and -2-fold more, respectively, than the baseline level. During 
hypoglycemic stress, glucagon release is increased and insulin release is decreased. Increased 
glucagon release is the main counterregulatory factor in the recovery of hypoglycemia31,32. 
However, the mechanism underlying hypoglycemia-induced glucagon release is uncertain. A 
number of studies suggest that the increase in glucagon release is due to the activation of the 
autonomic nervous system33"36. In contrast, our results suggested that a low glucose level 
directly increases glucagon release, since these experiments were performed in isolated 
perfused pancreas where there was no input from the autonomic nervous system. This 
finding is consistent with results observed in the isolated islets36 and perfused pancreata.37 
The basal glucose concentration maintained a constant level of glucagon through out the 
perfusion period, whereas a higher concentration of glucose (20 mmol/L) inhibited glucagon 
release, which was -60-70 % less than the baseline level. 
AVP (30 and 300 pmol/L) increased glucagon release in the presence of 0,1.4, or 5.5 
mmol/L glucose, whereas only 300 pmol/L AVP increased glucagon release at 20 mmol/L 
glucose. Thus, this increase was in a glucose concentration-dependent manner; the lower the 
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glucose concentration, the greater the enhancement of A VP-induced glucagon release. In 
experiments using mouse islets, as expected, AVP induced a large increase in glucagon 
release at 0 glucose and less glucagon release in the presence of glucose concentrations of 3-
7 mmol/L.20 Surprisingly, in mouse islets at higher glucose concentrations (15-20 mmol/L), 
AVP increased glucagon release from the mouse islets to the same extent as at 0 glucose.20 
We failed to observe such changes in the perfused rat pancreas. AVP (3-30 pmol/L) 
increased glucagon but not insulin release from the perfused rat pancreas (our unpublished 
data). These findings suggested that a-cells are more sensitive to AVP than p-cells in 
hormone release. Our findings are consistent with those obtained from the perfused rat 
pancreas10 and isolated rat islets18 and different from those obtained from the mouse islets.20 
In addition, these findings indicated that AVP may physiologically increase glucagon release, 
since AVP increased glucagon release at physiological concentrations of AVP plasma level 
(<30 pmol/L)39, while it failed to increase insulin release at these concentrations. 
AVP increased insulin and glucagon release but did not affect somatostatin release. 
This precludes that somatostatin may influence AVP- or glucose-induced insulin and 
glucagon release. The findings that AVP induced a large increase in glucagon release at low 
glucose concentrations without changing insulin release supports the notion that AVP has a 
direct effect on a-cells. In addition, the higher glucose concentration (20 mmol/L) inhibited 
glucagon release, which was -60-70% less than the baseline level. Under these conditions, 
AVP (30 pmol/L) failed to change glucagon release, whereas administration of AVP (300 
pmol/L) only induced a transient glucagon release. On the other hand, AVP (300 pmol/L) 
induced a large increase in insulin release, which supports the notion that AVP has a direct 
effect on P-cells. 
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In conclusion, AVP may increase insulin and glucagon release by a direct action on 
p- and a-cells, respectively. These increases are glucose-dependent; the higher the glucose 
concentration, the greater the enhancement of A VP-induced insulin release. In contrast, the 
lower the glucose concentration, the greater the enhancement of AVP induced glucagon 
release. AVP not only can enhance glucose-induced insulin release, but also can initiate 
insulin release, a-cells are much more sensitive to AVP than (3-cells in hormone release. 
Furthermore, our results confirmed the previous findings that hypoglycemia directly 
increases glucagon and decreases insulin release 
ACKNOWLEDGMENTS 
We thank the Hashemite Kingdom of Jordan and Jordan University of Science and 
Technology for the partial support of this study. Also we thank Dr. David L. Hopper for his 
assistance in statistical analysis. 
REFERENCES 
1. Russell JT, Brownstein MJ, Gainer H: Biosynthesis of vasopressin, oxytocin and 
neurophysin: Isolation and characterization of two common precursors 
(propressophysin and prooxyphysin). Endocrinology 107: 1880-1891,1990. 
2. Ang VT. Jenkins JS: Neurohypophysial hormones in the adrenal medulla. J Clin 
Endocrinol Metab 58: 688-691,1984. 
3. Amico J A, Finn FM, Haldar J: Oxytocin and vasopressin are present in human and rat 
pancreas. Am J Med Sci 296: 303-307,1988. 
4. Kirk CJ, Rodrigues LM, Hems DA: The influence of vasopressin and related peptides on 
glycogen phosphorylase activity and phosphatidylinositol metabolism in hepatocytes. 
Biochem J 178:493-496, 1979. 
63 
5. McNichol AM, Murry JE, Mcmeekin W: Vasopressin stimulation of cell proliferation in 
the rat pituitary gland in vitro. J Endocrinol 126: 255-259, 1990. 
6. Sperti G, Colucci WS: Calcium influx modulates DNA synthesis and proliferation in 
A7r5 vascular smooth muscle cells. Eur J Pharmacol 206: 279-284,1991. 
7. Fox AW, Friedman PA, Abel PW: Vasopressin receptor mediated contraction and 
[^H] inositol metabolism in rat tail artery 135: 1-10,1987. 
8. Tilders FJ, Berkenbosch F, Vermes I, Linton EA, Smelik PG: Role of epinephrine and 
vasopressin in the control of the pituitary-adrenal response to stress. Fed Proc 44:155-
160,1985. 
9. Grazzini E, Lodboerer AM, Perez-Martin A, Joubert D, Guillon G: Molecular and 
functional characterization of Vlb vasopressin receptor in rat adrenal medulla. 
Endocrinology 137: 3906-3914, 1996. 
10. Dunning BE, Moltz JH, Fawcett CP: Modulation of insulin and glucagon release from 
the perfused rat pancreases by the neurohypophysial hormones and by desamino-D-
arginine vasopressin (DDAVP). Peptides 5: 871-875,1984. 
11. Chen TH, Lee B, Hsu WH: Arginine vasopressin-stimulated insulin release and 
elevation of intracellular Ca2~ concentration in rat insulinoma cells: influences of a 
phospholipase C inhibitor l-[6-[[17 (i-methoxyyestra-1,3,5 ( 10)-trien-17-yl]-1H-
pyrrole-2,5-dione (U-73122) and a phospholipase A: inhibitor N-(p-Amylcinnamoyl) 
anthranilic acid. J Pharmacol Exp Ther 270: 900-904,1994. 
12 Yibchok-Anun S, Hsu WH: Effect of arginine vasopressin and oxytocin on glucagon 
release from clonal a-cell line In-Rl-G9: Involvement of Vib receptors. Life Sci 63: 
1871-1878, 1998. 
13 Yibchok-Anun S, Cheng H, Heine PA, Hsu WH: Characterization of receptors mediating 
A VP- and OT-induced glucagon release from the rat pancreas. Am J Physiol 
277:E56-E2, 1999. 
14. Richardson SB, Eyler N, Twente S, Monaco M, Altszuler N, Gibson M: Effects of 
vasopressin on insulin release and inositol phosphate production in a hamster beta cell 
line (HIT). Endocrinology 126: 1047-1052, 1990. 
64 
15. Li G, Pralong WF, Pittet D, Mayr GW, Schlege W, Wollheim CB: Inositol 
tetrakisphophate isomers and elevation of cytosolic Ca2+ in vasopressin-stimulated 
insulin-secreting RINmSF cells. J. Biol. Chem. 267:4349-4356, 1996. 
16. Lee B, Yang C, Chen TH, al-Azawi N, Hsu WH: Effect of A VP and oxytocin on insulin 
release: involvement of Vtb receptors. Am J Physiol 269:E1095-E1100, 1995. 
17. Yibchok-Anun S, Cheng H, Ter-Hsin Chen, Hsu WH: Mechanisms of A VP-induced 
glucagon release in clonal a-cells In-Rl-G9: involvement of Ca " -dependent and -
independent pathways. Br J Pharmacol 129: 257-264,2000. 
18. Dunning BE, Moltz JH, Fawcett CP: Actions of neurohypophysial peptides on 
pancreatic hormone release. Am J Physiol 246: E108-E114,1984. 
19. Gao ZY, Drews G. Nenquin M, Plant TD, Henquin JC: Mechanisms of the stimulation 
of insulin release by arginine-vasopressin in normal mouse islets. J Biol Chem 265: 
15724-15730, 1990. 
20. Gao ZY, Gerard M, Henquin JC: Glucose- and concentration-dependence of 
vasopressin-induced hormone release by mouse pancreatic islets. Regul Pept 38: 89-
98, 1992. 
21. Khalaf LJ, Taylor KW: Pertussis toxin reverses the inhibition of insulin secretion caused 
by [Arg8]vasopressin in rat pancreatic islets. FEBS Lett 231: 148-150, 1988. 
22. Richardson SB, Eyler N, Twente S, Monaco M, Altszuler N, Gibson M: Effects of 
vasopressin on insulin secretion and inositol phosphate production in a hamster beta 
cell line (HIT). Endocrinology 126: 1047-1052, 1990. 
23. Yang C, Hsu WH: Stimulatory effect of bradykinin on insulin release from the perfused 
rat pancreas. Am J Physiol 288: E1027-E1030, 1995. 
24. Hale CN, Randle PJ : Immunoassay of insulin with insulin antibody precipitate. Biochem 
J 88: 137-146, 1963. 
25. Patel YC: Somatostatin radioimmunoassay of somatosatin-related peptides, in Pohl SL, 
Lamer SL (eds): Methods in Diabetes Research. New York, NY, wiley, 1984, pp 307-
327. 
26. Kenmochi T, Miyamoto M, Sasaki H, Une S, Nakagawa Y, Moldovan S, Benhamou PY, 
65 
Brunicardi FC, Tanaka H, Mullen Y. LAP-1 cold preservation solution for isolation of high-
quality human pancreatic islets. Pancreas 17: 367-377, 1998. 
27. Grodsky GM, Bennett LL: Insulin released from the isolated pancreas in the absence of 
insulinogenesis Proc Soc exp Biol Med 6: 554-579, 1969. 
28. Charles MA, Lawecki J, Pictet R, Grodsky GM: Insulin secretion. Interrelationships of 
glucose, cyclic adenosines:5-monophosphate, and calcium. J Biol Chem 250: 6134-
6140, 1975. 
29. Cerasi E, Luft R: The plasma insulin response to glucose infusion in healthy subjects and 
in diabetes mellitus. Acta Endocrinol (Copenh) 55: 278-304, 1967. 
30. Cerasi E, Luft R: Insulin response to glucose infusion in diabetic and non-diabetic 
monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol 
(Copenh) 55: 330-345, 1967. 
31. Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon N, Karam J, Lewis S, Kaplan R, 
Schultz T, Cryer P: Hormonal mechanisms of recovery from insulin-induced 
hypoglycemia in man. Am J Physiol 236: E380-E385, 1979. 
32. Cryer PE: Glucose counterregulation in man. Diabetes 30: 261-264, 1981. 
33. Havel PJ, Taborsky GJ Jr: The contribution of the autonomic nervous system to changes 
of glucagon and insulin secretion during hypoglycemic stress. Endocr Rev 10: 332-
350, 1989. 
34. Havel PJ, Valverde C: Autonomic mediation of glucagon secretion during insulin-
induced hypoglycemia in rhesus monkeys. Diabetes 45: 960-966,1996. 
35. Havel PJ, Mundinger TO, Taborsky GJ Jr. Pancreatic sympathetic nerves contribute to 
increased glucagon secretion during severe hypoglycemia in dogs. Am J Physiol 
270:E20-E26, 1996. 
36. Oliver JR, Williams VL, Wright PH: Studies on glucagon secretion using isolated islets 
of Langerhans of the rat. Diabetologia 12:301-306, 1976. 
37. Weir GC, Knowlton SD, Martin DB: Glucagon secretion from the perfused rat pancreas. 
Studies with glucose and catecholamines. J Clin Invest 54:1403-1412, 1974. 
38. Thibonnier M: Signal transduction of VI-vascular vasopressin receptors. Regul Pept 38: 
1-11, 1992. 
Fig 1. Effect of glucose (0, 1.4, 5.5, and 20 mmol/L) on insulin (A) and glucagon (B) release 
from the perfused rat pancreas. In this and all other figures, basal glucose (5.5 mmol/L) was 
administered during the equilibration period of 20 minutes preceded time 0 followed by 
another 12 minutes of the baseline period. Various concentrations of glucose were given for 
30 minutes (glucose treatment), followed by 8 minutes of the washout period (wash). By 
calculating the areas under the curves for glucose (0,1.4, and 20 mmol/L) and comparing 
them with those of the control group (5.5 mmol/L glucose), both 0 and 1.4 mmol/L glucose 
significantly (P < .05) decreased insulin release, whereas 20 mmol/L glucose significantly 
increased insulin release. In contrast, both 0 and 1.4 mmol/L glucose significantly increased 
glucagon release, whereas 20 mmol/L glucose significantly decreased glucagon release. 
Values are the mean ± SE (n=4). •, Basal control (5.5 mmol/L glucose); O, 0 glucose; V, 
1.4 mmol/L glucose; O, 20 mmol/L glucose. Range of baseline insulin and glucagon 
concentrations of effluents were 1045-2507 and 50-68 pg/ml, respectively. 
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Fig 2. Effect of AVP (30 and 300 pmol/L) on insulin release from the perfused rat pancreas. The 
treatment protocol was the same as in Fig I. AVP was given for 30 minutes. Glucose concentrations 
were 0 (A), 1.4 (B), 5.5 (C), and 20nnnol/L (D), respectively. By calculating the areas under the curves 
for AVP and comparing them with those of the control group, 30 pmol/L AVP did not significantly 
changed insulin release in all tested glucose concentrations, whereas 300 pmol/L AVP significantly (P < 
.05) increased insulin release in 5.5 and 20 mmol/L glucose groups. Values are the mean ± SE (n=4). 
O, Control (glucose without AVP); V, AVP (30 pmol/L); D, AVP (300 pmol/L). Range of baseline 
insulin concentrations of effluents was 1045-3137 pg/ml. The F ratios are as follows: AVP 
concentration, P < .0001 ; glucose concentration, P < .0001 ; AVP concentration x glucose concentration, 
Pc.OOOl. 
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Fig 3. Effect of AVP (30 and 300 pmol/L) on glucagon release from the perfused rat pancreas. The 
treatment protocol was the same as in Fig 1. AVP was given for 30 minutes. Glucose concentrations 
were 0 (A), 1.4 (B), 5.5 (C), and 20mmol/L (D), respectively. By calculating the areas under the curves 
for AVP and comparing them with those of the control group, both 30 and 300 pmol/L AVP 
significantly (P < .05) increased glucagon release in 0, 1.4, and 5.5 mmol/L glucose groups, whereas 
only 300 pmol/L AVP significantly (P < .05) increased glucagon release at 20 mmol/L glucose group. 
Values are the mean ± SE (n=4). O, Control (glucose without AVP); V, AVP (30 pmol/L); 0, AVP 
(300 pmol/L). Range of baseline glucagon concentrations of effluents was 50-75 pg/ml. The F ratios 
are as follows: AVP concentration, P < .0001 ; glucose concentration, P < .0001 ; AVP concentration x 
glucose concentration, P < .0001. 
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Fig 4. Schematic representation of data plotted showing the glucose dependency. Values are 
the mean ± SE (n=4) obtained by calculating the areas under the curves of the 30 minutes 
insulin (A) or glucagon (B) release and expressed as a percentage of basal glucose (5.5 
mmol/L) control group. O, Control (glucose without AVP); V, AVP (30 pmol/L); D, AVP 
(300 pmol/L). 
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ABSTRACT 
The purpose of this study was to investigate the intracellular mechanism of 
cAMP/PKA-dependent enhancement of arginine vasopressin (AVP)-induced glucagon 
release. Increasing intracellular cAMP levels, by using forskolin or by preventing cAMP 
degradation with the phosphodiestrease inhibitor IB MX, enhanced A VP-induced glucagon 
release from the perfused rat pancreas and the clonal a-cells InRlG9. Pre-treatment with 
SQ-22536, an adenylyl cyclase inhibitor, abolished both the effect of forskolin on glucagon 
release and the enhancement effect of forskolin on A VP-induced glucagon release. In 
addition, SQ-22536 abolished forskolin-induced cAMP production. Furthermore, the 
inactive analog of forskolin neither increased glucagon release nor enhanced the effect of 
A VP-induced glucagon release. cAMP produced its effects through the stimulation of PKA, 
as a selective PKA inhibitor H-89 reduced the effect of forskolin on AVP induced-glucagon 
release and abolished the effect of forskolin on glucagon release. The effect of forskolin and 
IB MX on glucagon release was Ca2"-independent since both chemicals induced glucagon 
release to the same extent in the presence or absence of Ca2+. However, forskolin and IBMX 
enhanced A VP-induced glucagon release in Ca2*-containing medium but not in Ca2+-free 
medium. CaMK II plays a partial role in A VP-induced glucagon release, since the selective 
inhibitor, KN93, partially blocked A VP-induced glucagon release and forskolin/A VP-
induced glucagon release. 
The fact that glucagon release was prolonged with forskolin treatment in the perfused 
rat pancreas and from InRlG9 cells led us to hypothesize that PKA promotes the 
mobilization of secretory granules from the reserve pool (RP) to the readily releasable pool 
(RRP). To test this hypothesis, InRlG9 cells were loaded with styryl dye FM1-43. The 
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combination of AVP and forskolin induced more increase in fluorescence intensity (~ 4.8 
fold of the control group) than AVP or forskolin alone (~ 2.1 and ~ 1.5 fold of the control 
group, respectively), which reflects an increase in the number of secretory granule 
membranes fused with the plasma membrane and in the size of the RRP. Secretory granules 
in the RP are thought to be reversibly connected to the actin-based cytoskeleton by synapsin 
I. Synapsin I has been proposed to play a major structural role in the assembly and 
maintenance of the RP secretory granules as well as a dynamic role in controlling secretory 
granules transitions from RP to RRP. Pretreatment with antisynapsin I antibody abolished 
the effect of forskolin/A VP-induced glucagon release but not glucagon release in the control, 
AVP, or forskolin groups. In addition, FM 1-43 loading experiments showed that synapsin I 
is involved in recruitment of secretory granules from RP to RRP. Our finding suggested that 
I ) cAMP/PKA does not increase [Ca2~], nor does it enhance A VP-induced [Ca2+]i increase, 
2) cAMP/PKA enhancement of A VP-induced glucagon release is Ca'^-dependent, 3) CaMK 
II plays a partial role in the enhancement of A VP-induced glucagon release, 4) cAMP, acting 
through PKA, increases the number of secretory granules in RRP by mobilization of granules 
from the RP, an action mediated by Synapsin I. 
KEY WORDS 
Arginine vasopressin; Glucagon; Exocytosis; cAMP/PKA, FM 1-43, readily 
releasable pool, Synapsin I. 
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INTRODUCTION 
Glucagon plays a key role in maintaining glucose homeostasis. It is secreted from the 
pancreatic a-cells in response to low blood glucose levels and stimulates hepatic glucose 
output by increasing glycogeno lysis and gluconeogenesis, while at the same time inhibiting 
glycolysis (Burcelin et al., 1996). Understanding the regulation of glucagon release may 
contribute to a better control of type 2 diabetes because excessive glucagon release in 
diabetic patients further aggravates the hyperglycemia caused by low insulin release (Unger 
and Oric, 1995). 
Arginine vasopressin (AVP), a neurohypophysial nonapeptide hormone, stimulates 
the release of a number of hormones including catecholamine (Grazzini and Lodboerer, 
1996), insulin (Dunning et al., 1984; Chen et al., 1994) and glucagon (Yibchok-anun and 
Hsu, 1998; Yibchok-anun et al., 1999). AVP induces glucagon release through Ca 2 -
dependent and -independent pathways (Yibchok-anun, 2000). In the case of the Ca"2 -
dependent pathway, V ib receptor-coupled Gq protein activates phospholipase C, which in turn 
catalyzes the hydrolysis of phospatidylinositol 4,5-bisphosphate (PIP2) to generate 
diacylglycerol and inositol 1,4,5-triphosphate (IP3). Diacylglycerol activates PKC and IP3 
induces Ca~2 release from the endoplasmic reticulum, which leads to Ca>2 influx. Both Ca 2 
release and Ca"2 influx contribute to A VP-induced glucagon release (Yibchok-anun et al., 
2000). 
Changes in the intracellular cyclic AMP (cAMP) concentration play an important role 
in the adjustment of cellular processes initiated by hormones, neurotransmitters and nutrients 
(Sutherland, 1972). In pancreatic p-cells, cAMP has been found to potentiate Ca2+ -
dependent exocytosis (Wollheim et al., 1987; Gillis and Misler, 1993). The ability of cAMP 
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to stimulate insulin release can be prevented by Rp-cAMPS, a specific inhibitor of PKA 
(Wollheim et al., 1987). Experiments on permeabilized islets or (3-cells suggest that the 
principal action of cAMP is exerted downstream of [Ca2+]j elevation(Ammala et al., 1993; 
Renstrom et al., 1997). Ammala et al. (1993) used capacitance measurements to quantify 
exocytosis and showed that this effect accounted for up to 80% of the exocytosis. c AMP -
induced stimulation of exocytosis involves both increasing the release probability of 
secretory granules already in the readily releasable pool (RRP) and by accelerating the 
refilling of this pool (Renstrom et al., 1997). The ability of cAMP to stimulate exocytosis is 
not exclusive to the pancreatic (3-cell, since it also enhances glucagon release from pancreatic 
a-cells (Gromada et al., 1997). Forskolin evokes PKA-dependent potentiation of exocytosis 
by enhancing Ca2^ influx through L-type channels, which accounts for less than 30% of total 
stimulatory effect (Gromada et al., 1997). The majority of the stimulatory effect of forskolin 
(70%) resulted from acceleration of granule mobilization and thus increasing the size of the 
RRP (Gromada et al., 1997). 
The transition of secretory granules between the reserve pool (RP) and RRP are 
subject to extensive regulation, much of which is mediated by Ca21- (Pyle et al., 2000). The 
secretory granule cycle is regulated by increasing the number of vesicles in RRP through 
mobilization of vesicles from RP (regulation of the releasable pools), or by increasing the 
number of docked vesicles that are ready for fusion (release probability of docked vesicles) 
(Turner et al., 1999). The filling of RRP, measured as recovery from depletion, is enhanced 
by elevating [Ca2*], (Von Ruden and Neher, 1993). Protein Kinase C (PKC) (Gillis et al., 
1996; Stevens et al., 1998; Smith et al., 1998; Sudhof, 2000) and PKA (Renstrom et al., 
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1997; Gromada et al., 1997) are also involved in the regulation of the size of RPP in other 
cell systems by mobilizing the secretory vesicles from RP to RRP. 
The RRP is thought to correspond to the number of synaptic vesicles morphologically 
docked to the presynaptic membrane that can be released (Rosenmund and Stevens, 1996; 
Dobrunz and Stevens, 1997). Synaptic vesicles in the RP are organized in clusters in which 
the vesicles are reversibly linked to the actin-based cytoskeleton by a family of abundant 
synaptic vesicle-associated phosphoproteins, the synapsins (Benfenati et al., 1993; Ceccaldi 
et al., 1995; Pieribone et al., 1995; Kuromi and Kidokoro, 1998). Synapsin I has been 
proposed to play a major structural role in the assembly and maintenance of the RP of 
synaptic vesicles as well as a dynamic role in controlling synaptic vesicle transitions from RP 
to RRP (Greengard et al., 1993; Brodin et al., 1997; Benfenati et al., 1999). Synapsin I links 
synaptic vesicles to the cytoskeleton, thus regulating the availability of synaptic vesicles for 
RRP (Benfenati et al., 1993, Ceccaldi et al., 1995). Synapsin I is phosphorylated at the N-
terminus by CaMK II and PKA (Sudhof, 1995). Phosphorylation of synapsin I releases the 
connected vesicles and allow mobilization of these vesicles from RP to RRP (Greengard et 
al., 1993; Brodin et al., 1997; Benfenati et al., 1999; Hosaka et al., 1999). Neither the 
function of synapsin I phosphorylation nor the significance of phosphorylation of PKA is 
clear in pancreatic a-cells. 
In a preliminary study, we found that elevation of cAMP via forskolin, enhanced 
A VP-induced glucagon release from the perfused rat pancreas and InRlG9 cells. Thereafter, 
we investigated the intracellular molecular mechanism of cAMP/PKA-dependent 
enhancement of A VP-induced glucagon release, particularly at the level of exocytosis. 
Although the effects of cAMP on secretion have been widely studied, in this study, we 
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present the first work demonstrating the effects of cAMP/PKA on single cell exocytotic 
episodes and the involvement of synapsin I on glucagon-secreting cells (InRlG9). Our 
results suggested that cAMP, acting through PKA, increases the number of secretory 
granules in the RRP by mobilization of granules from the RP, an action mediated by 
Synapsin I. 
MATERIALS AND METHODS 
Pancreatic perfusion 
Male Sprague-Dawley rats (300-400 g) were randomly used. The rats were 
anesthetized with pentobarbital sodium (60 mg/kg, intrapertoneally), and were maintained at 
37°C on a hot plate during the experiment. Pancreatic perfusion was performed as 
previously described (Yang and Hsu, 1995). Briefly, after cannulation of the celiac artery, 
the rat pancreas was immediately perfused with Krebs-Ringer bicarbonate (KRB) solution 
supplemented with 20 mmol/L HEPES, 5.5 mmol/L glucose, 1% dextran, and 0.2% bovine 
serum albumin as a basal medium. The KRB was maintained at pH 7.4 and continuously 
aerated with 95% O: - 5% CO?. The rats were euthanatized by the induction of 
pneumothorax immediately following the cannulation of the portal vein and the beginning of 
the flow. 
The first 20 min of perfusion was considered as an equilibration period. 
Subsequently, the effluent fluid was collected every minute from the cannula in the portal 
vein. The flow rate was set at 1 ml/min. After a baseline period of 12 min, the perfusate 
containing AVP (30 pmol/L), forskolin (10 nM), or forskolin + AVP was administered for 30 
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min. This was followed by a washout period during which the basal medium was 
administered for 10 min. Control experiments were performed following the same protocol 
except that KRB was used in place of the drugs. In all experiments, arginine (1 mmol/L) was 
administered at the end of the experiment for 8 minutes to confirm the normal secretory 
capacity under experimental condition. The effluent fluids were kept at 4°C and assayed 
within 6 h for glucagon using radioimmunoassay as previously described (Yibchock-anun 
and Hsu, 1998). 
Cell culture 
The hamster glucagonoma InRlG9 cells were maintained in RPMI-1640 medium 
with 10% fetal bovine serum and aerated with 5% COi-95% air at 37°C. All experiments 
were performed using cells from passages 24 to 30. 
Perifusion of InRlG9 cells 
Glucagon release was measured under perifusion condition as previously described 
(Kikuchi et al., 1974; Daniel et al., 1999). Briefly, InRlG9 cells were grown in custom-
made coverslips, which were placed in a perifusion chamber. Each covers lip was exposed to 
one of the following treatments: control, which was treated with Krebs-Ringer bicarbonate 
(KRB) alone; AVP (100 nM); forskolin (10 fiM); and the combination of AVP and forskolin. 
At the end of the experiment, the cells were treated with KC140 mM to stimulate glucagon 
release, in order to confirm that the cells retained the normal secretory capacity under the 
experimental conditions. 
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Static incubation 
InRlG9 cells were plated into Corning 24-well plates at 105 cells/well and were 
grown for 3-4 days. The culture medium was then removed and replaced with modified 
Krebs-Ringer bicarbonate buffer (KRB) containing (in mM): 136 NaCl, 4.8 KC1, 2.5 CaCb, 
1.2 KH2P04, 1.2 MgSCX, 5 NaHCQ3,10 HEPES, 1.67 glucose and 0.1% BSA, pH 7.4. For 
determination of AVP, forskolin (or EBMX), forskolin (or IBMX) + AVP effects on glucagon 
release, the cells were incubated at 37°C for 15 min after preincubation with KRB for 15 
min. For Ca2+-free experiments, cells were incubated at 37°C with AVP or other agonists in 
Ca2"-free KRB containing 30 jiM EOT A for 15 min after preincubation with Ca2+-containing 
KRB for 15 min. The following drugs were used in the study: SQ-22536, an adyenylyl 
cyclase inhibitor; KN93, a selective CaM kinase II inhibitor, were given 30 minutes prior to 
the administration of AVP or other agonists. l,2-bis-(o-Aminophenoxy)-ethane-N,N,N',N'-
tetraacetic acid acetoxymethyl ester (B APT A-AM), an intracellular Ca2+ chelator, was given 
30 min in Ca2"-containing KRB before the administration of different agonists. H-89, a 
selective inhibitor for PKA, was given 24 h before the experiment. The cells were then 
treated with AVP or other agonist. The concentration of glucagon in the media was 
measured by radioimmunoassay as previously described (Yibchock-anun and Hsu, 1998). 
Intracellular delivery of antisynapsin I antibody 
Intracellular delivery of antisynapsin I antibody was performed using a recently 
developed lipid-mediated delivery system (BioPORTER, Gene Therapy System, San Diego, 
CA). This protein delivery system is fast and displays no significant toxicity and makes 
protein delivery into cultured cells as convenient, effective, and reliable as DNAtransfection 
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(Zelphati et al., 2001). It is composed of a new trifluoroacetylated lipopolyamine (TFA-
DODAPL) and dioleoyl phosphatidylethanolamine (DOPE). The cationic formulation 
successfully delivered antibodies, dextran sulfates, phycobiliproteins, albumin, and enzymes 
(P-galactosidase and proteases) into the cytoplasm of numerous adherent and suspension cells 
(Zelphati et al., 2001). Undiluted antisyapsin I antibody (Calbiochem-Novabiochem Co., 
San Diego, CA) was delivered into InRlG9 cells following the manufacture's protocol. 
Briefly, In-Rl-G9 cells were plated into Coming 48-well plates at 105 cells/well (or on cover 
slips at 104 cells/cover slip) and were grown for 2 days. Antisynapsin I antibody (1.5 fxl) (or 
normal rabbit plasma as control) was mixed with 1.5 |xl of the protein delivery reagent and 
150 \x\ of serum free RPMI medium and added to each well. The cells were incubated at 
37°C for 4 h. The culture medium was then removed and replaced by KRB following the 
same procedures as described in static incubation for the 48-well plates and the single cell 
exocytosis for the cover slips. 
Measurement of /Ca"/, in cell suspension 
20 x 106 cells were loaded with 2 pM fura-2 acetoxymethyl ester (fura-2AM) in KRB 
for 30 min at 37°C. The loaded cells were centrifuged (300 x g, 2 min), then resuspended at 
a concentration of 2 x 106 cells/ml with KRB containing (in mM): 136 NaCl, 4.8 KC1,1.5 
CaCb, 1.2 KH2PO4, 1.2 MgS04.10 HEPES, 1.67 glucose and 0.1% BSA and kept at 24°C 
until use. The 340/380 nm fluorescence ratios were monitored by a SLM-8000 
spectrofluorometer (SLM instruments, Urbana, IL). The [Ca2*], was calibrated as previously 
described (Hsu et. al., 1991). 
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cAMP measurement 
Intracellular cAMP concentrations were measured in InRlG9 cells after 15 min of 
static incubation with AVP, forskolin (or IB MX), or the combination of AVP and forskolin 
(or IB MX). SQ-22536, an adyenylyl cyclase inhibitor, was given 30 min before the 
administration of different agonists. After the experiment, cells were scraped from the plate 
in 0.01 N HC1 and incubated in the water bath at 75 °C for 20 min to inactivate 
phosphodiesterase (PDE). After centrifugation, the supernatant was removed and neutralized 
by 0.01 NaOH and diluted in the assay buffer as needed. The cAMP concentrations were 
determined using RLA as previously described (Richards et al., 1979; Chen and Hsu, 1994). 
Single cell exocytosis 
lnRlG9 cells were grown in custom-made circular cover slips. The cells were loaded 
with styryl dye FM 1-43 (2 fiM) and exposed to one of the 4 treatments for 4 min: control, 
treated with KRB alone; 100 nM AVP; 10 (iM forskolin, and the combination of AVP and 
forskolin. Antisynapsin antibody I (1:100) was given 4 h before the experiment as described 
above in the intracellular delivery of antisynapsin I antibody with TFA-DODAPL: DOPE. 
Then the cells were exposed to the same 4 treatment groups above. At the end of the 
experiment, cells were rinsed 8 times with KRB to remove the dye from the external plasma 
membrane and fixed with 4% paraformaldehyde. 
Image Analysis 
Fluorescence imaging and quantitative analysis of fluorescence images were 
performed as previously described (Uemura and Greenlee, 2001). Briefly, digital images of 
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the cells were captured using a Leica TCS NT laser confocal microscope under a 60X 
objective. The NTH image software was used to analyze relative fluorescence intensity of 
FM1-43. 
Test Agents 
AVP, cAMP, forskolin, 1,9 dideoxyforskolin and IB MX were purchased from Sigma 
Chemical Co. (St. Lous, MO). FM 1-43 was purchased from molecular Probes (Eugene, OR), 
B APT A-AM, KN-93 and H-89 were purchased from Biomol Research Laboratories 
(Plymouth Meeting, PA). SQ-22536 was purchased from Squipp (Princeton, NT). Glucagon 
standard was donated by Eli Lilly laboratories (Indianapolis, IN). Glucagon antibody was 
donated by Dr. Joseph Dunbar of Wayne State University (Detroit, MI). 125I-gIucagon was 
purchased from Linco Research (St. Charles, MO). The antiserum against cAMP was a gift 
of the National Institute of Diabetes and Digestive and Kidney Disease, National Hormone 
and Pituitary Program, and the University of Maryland, School of Medicine. 
Data Expression and Statistical Analysis 
The effluent concentrations of glucagon in rat pancreatic perfusion and the peri fused 
InRlG9 cells were expressed as a percentage of the baseline level (mean of last 5 baseline 
values) in mean ± SE. The area under the curve for the treatment period of 30 min was 
calculated using the Transforms and Regressions (Sigma Plot 5.0; SPSS Inc., Chicago, IL). 
Data were analyzed by analysis of variance using the SAS Proc General Linear Means 
procedure. Individual mean comparisons were calculated using the F test. The significance 
level was set at P < .05. 
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RESULTS 
Enhancement by forskolin of A VP-induced glucagon release from the perfused rat 
pancreas. We determined the possible involvement of the interaction between cAMP/PKA 
and PLC pathways in rat pancreatic perfusion. The effects of forskolin, an adenylyl cyclase 
activator, on A VP-induced glucagon release were investigated. Forskolin (10 fxM) enhanced 
the effect of AVP (30 pM) on glucagon release (a peak of -2.4 fold and -4.4 fold of the 
baseline level for AVP and the combination of AVP and forskolin, respectively) (Fig. I). 
This enhancement was more prominent in the sustained phase than that in the peak phase 
(-1.5-2.0 fold and -5-6 fold of the baseline level for AVP and the combination of AVP and 
forskolin, respectively) (Fig. I). Forskolin alone caused a small increase in glucaogon 
release (- 1.6 fold of the baseline level) (Fig. 1). 
Enhancement by forskolin of A VP-induced glucagon release from perifused InRlG9 cells. 
The synthesis and release of glucagon by lnR!G9 cells share the basic characteristics of a-
cells of the endocrine pancreas (Rorsman et al., 1991). Therefore, we used InRlG9 cells as a 
model for the a-cetls of the pancreas to study the mechanisms underlying this enhancement. 
Glucagon release was measured under perifusion condition (Kikuchi et al., 1974; Daniel et 
al., 1999). Forskolin (10 |oM) enhanced the effect of AVP (100 riM) on glucagon release (a 
peak of -3 fold and -7 fold of the baseline level for AVP and the combination of AVP and 
forskolin, respectively) (Fig. 2). This enhancement was still present in the sustained phase 
(-1.5 fold and -2-3 fold of the baseline level for AVP and the combination of AVP and 
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forskolin, respectively) (Fig. 2). Forskolin alone caused a small increase in glucagon release 
(~ 1.7 fold of the baseline level) (Fig. 2). In all experiments, administration of 40 mM KC1 
increased glucagon release at the end of the experiment (data not shown). 
Enhancement by forskolin and IBMX of A VP-induced glucagon release in static secretion. 
Forskolin (10 pM) and IBMX (100 fiM) respectively enhanced AVP (100 nM>induced 
glucagon release from InRlG9 cells in static secretion experiments (Fig. 3). Forskolin (0.1-
10 |iM) enhanced the effect of AVP on glucagon release in a concentration-dependent 
manner (Fig. 4). 
The above data suggest that an increase in intracellular cAMP level may be involved 
in the enhancement of A VP-induced glucagon release. In order to investigate this possibility, 
we examined the effect of SQ-22536, an adenylyl cyclase inhibitor, on forskolin-induced 
enhancement. Pre-incubation with SQ-22536 (100 pM for 30 min), abolished both the effect 
of forskolin-induced glucagon release and the enhancement effect of forskolin on A VP-
induced glucagon release (Fig. 5). Furthermore, the inactive analog of forskolin, 1,9 
dideoxyforskolin, neither increased glucagon release nor enhanced the effect of AVP on 
glucagon release (Fig. 6). 
To determine whether PKA plays a role in this enhancement, we studied the effect of 
H-89, a selective inhibitor of PKA (Dodge and Sanborn, 1998). Preincubation of H-89 (1 
piM for 24 h) reduced the effect of forskolin (1 |iM)-induced enhancement (Fig. 7). In 
addition, H-89 abolished the effect of forskolin-induced glucagon release, while it failed to 
inhibit A VP-induced glucagon release (Fig. 7). 
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Effect of SQ-22536 on forskolin- and IBMX-induced increase in cAMP. The addition of 
forskolin or IB MX would be expected to promote an increase in cAMP level and 
consequently activate PKA. Therefore, we next measured the cAMP levels in forskolin, 
IBMX and A VP treated groups. Forskolin (10 |xM) caused -1.1 fold of the baseline level 
(Fig. 8). Neither A VP (100 nM) alone nor the combination of A VP and forskolin caused a 
further increase in cAMP production when compared with the control and forskolin groups, 
respectively (Fig. 8). IBMX caused ~2.6 fold of the baseline level (Fig. 9). As expected, the 
cAMP level in the combination of A VP and IBMX group was not different from IBMX 
alone (Fig. 9). Therefore, the effects of forskolin and IBMX on A VP-induced glucagon 
release cannot be explained by further increase in cAMP level (Figs. 8 and 9). 
Similar to the results obtained in the glucagon release experiments, pretreatment with 
SQ-22536 elicited a remarkable reduction on forskolin-induced cAMP production (Fig. 10). 
Furthermore, the inactive analog of forskolin did not change the cAMP levels when 
compared with the control group (Fig. 8). Therefore, the increase in cAMP production is 
essential for the enhancement of A VP-induced glucagon release. 
Enhancement by cAMP/PKA on A VP-induced glucagon release at a site distal to the 
elevation of fCa2+/i. Forskolin (10 |xM) did not enhance A VP (100 nM)-induced [Ca2^], in 
cell suspension experiments (Fig. 11). Forskolin alone did not increase [Ca2+]i (data not 
shown). These results suggest that cAMP/PKA enhances A VP-induced glucagon release in 
InRlG9 cells at a site distal to the elevation of [Ca2+]j. 
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Ca2+-dependency of the interaction between cAMP/PKA and A VP. Forskolin (10 (iM) and 
IB MX (100 |xM) enhanced A VP (100 nM)-induced glucagon release in Ca2+-containing 
medium but not in Ca2~-free medium (Figs. 12 and 13). The basal rate of glucagon release in 
Ca2~-free medium was ~46% less than that in Ca2"-contianing medium. In Ca2"-free 
medium, A VP (100 nM) still increased glucagon release -2.2-fold of the basal control level 
(Figs. 12 and 13). Forskolin and IBMX induced glucagon release in both Ca2*-containing 
and Ca^-free medium (Figs. 12 and 13). The effect of forskolin and IBMX on glucagon 
release was Ca2~-independent since both chemicals induced glucagon release to the same 
extent in the presence or absence of Ca2\ 
Furthermore, preincubating the cells with 25 |xM B APT A-AM, an intracellular Ca2~ 
chelator, in Ca2~-containing medium for 30 min reduced the effect of forskolin on A VP-
induced glucagon release (Fig. 14). This concentration of BAPTA-AM abolished A VP-
induced [Ca2~], increase (data not shown). A VP still increased glucagon release ~ 1.6-fold of 
the basal control level (Fig. 14). Forskolin increased glucagon release to the same extent in 
the presence or absence of BAPTA-AM (Fig. 14). BAPTA-AM alone did not significantly 
change glucagon release (Fig. 14). 
Role of Ca2+/ calmodulin-dependent protein kinase II (CaMK II). A Ca2+-dependent 
pathway largely mediates A VP-induced glucagon release (Yibchok-anun et al., 2000). Ca2+-
dependent regulatory mechanisms are often mediated by activation of calmodulin (CaM), 
which, in turn, activates a range of cellular proteins, such as CaMK H (Colbran et al., 1989; 
Means et al., 1991). Several lines of evidence suggest that CaM and/or CaMK II could be 
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involved in the regulation of PLC-Iinked Ca2+ signals (Hosey et al., 1986; Hill et al., 1988; 
McCarron et al., 1992; Zhang et al., 1993). To investigate the role of CaMK II activity in 
PLC-Iinked Ca2+ signals in InRlG9 cells and its role in the enhancement of A VP-induced 
glucagon release, we studied the effects of KN-93, a selective CaMK II inhibitor. KN93 (1 
jiM) partially blocked A VP-induced glucagon release and forskolin/AVP-induced glucagon 
release (Fig. 15). In contrast, KN-93 failed to inhibit forskolin-induced glucagon release 
(Fig. 15). 
Involvement of RRP. Our results from the perfused rat pancreas and InRlG9 cells suggested 
that cAMP/PKA may increase the size of RRP, leading to enhancement of AVP-induced 
glucagon release. Therefore, we used FM 1-43 as a fluorescent probe to study the effect of 
cAMP/PKA on RRP. A VP- and forskolin-induced exocytosis and increased the fluorescent 
intensity by ^2. l-fold and ~ 1.45-fold of the control group, respectively (Fig. 16). Forskolin 
enhanced AVP-induced exocytosis and increased the fluorescent intensity by ~4.8-fold of the 
control group (Fig. 16), which reflects an increase in the number of secretory granule 
membranes fused with the plasma membrane and an increase in the size of RRP. 
Involvement of Synapsin I. In neurons, synapsin I plays a key role in controlling the 
mobilization of the secretory vesicles from RP to RRP (Greengard et al., 1993; Benfenati et 
al.. 1999). We next investigated the involvement of synapsin I in cAMP/PKA enhanced 
AVP-induced glucagon release and its role in granule mobilization in InRlG9 cells. 
Pretreatment with antisynapsin I antibody in the presence of forskolin (10 |iM) and A VP 
(100 nM) for 4 h abolished the enhancement effect of forskolin on AVP-induced glucagon 
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release (Fig 17). Antisynapsin I antibody did not change glucagon release in the control, 
A VP or forskolin groups (Fig. 17). 
We further tested the involvement of synapsin I on the size of RRP. InRlG9 cells 
were pretreated with antisynapsin I antibody or normal rabbit plasma for 4 h in the presence 
of forskolin (10 |iM) and A VP (100 nM). Similar to the results obtained from glucagon 
release experiments, antisynapsin I antibody abolished the effect of forskolin on AVP-
induced exocytosis (Fig. 18). A VP- and forskolin-increased fluorescent intensity by -175% 
and -197% of the control group, respectively (Fig. 18). Antisynapsin I antibody did not 
change the exocytotic rate in A VP or forskolin groups when compared with A VP or forskolin 
groups that did not receive antisynapsin I antibody (Fig. 18). These results suggest that 
synapsin I is involved in the release of secretory vesicles from RP to refill RRP. 
DISCUSSION 
In the present study we investigated the contribution of the cAMP/PKA system to the 
regulation of glucagon release and the kinetics of an episode of exocytotic release. For this, 
the interaction between A VP and cAMP/PKA was studied using rat pancreatic perfusion and 
peri fused clonal a-cells InRlG9 cells. The results suggested that AVP-induced glucagon 
release is enhanced by cAMP/PKA system. Data from static secretion, [Ca2^], 
measurements, and exocytosis from individual InRlG9 cells were used to explore the 
mechanism of this enhancement. 
The cAMP signal transduction pathway is clearly involved in the enhancement of 
AVP-induced glucagon release. We first observed that increasing intracellular cAMP 
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formation by using forskolin or preventing c AMP degradation with the phosphodiestrease 
inhibitor IBMX, enhanced AVP-induced glucagon release. SQ-22536, an adenylyl cyclase 
inhibitor, abolished the stimulatory effect of forskolin on glucagon release and the 
enhancement effect of forskolin on AVP-induced glucagon release. In addition, SQ-22536 
abolished forskolin-induced cAMP production, which provides evidence that adenylyl 
cyclase activation is crucial to this enhancement. Furthermore, the inactive analog of 
forskolin neither increased glucagon release nor enhanced the effect of AVP on glucagon 
release. The signaling pathway used by cAMP to produce its effects seems to be through the 
stimulation of PKA, as H-89, a selective PKA inhibitor, reduced the effect of forskolin/AVP-
induced glucagon release and abolished the effect of forskolin induced glucagon release. 
The enhancement effect of cAMP/PKA on AVP-induced glucagon release is Ca2+-
dependent because forskolin and IBMX enhanced AVP-induced glucagon release in Ca2 -
containing medium but not in Ca2+-free medium. Furthermore, preincubating the cells with 
BAPTA-AM, an intracellular Ca2~ chelator, in Ca2+-containing medium reduced the effect of 
forskolin/A VP-induced glucagon release. This was expected since most of the exocytotic 
fusion is Ga2-dependent and the granule fusion, per se, occurs independently of protein 
kinase involvement and is thought to be mediated by the direct action of Ca2+ influx through 
Ca27phospholipid binding protein synaptotagmin (Lang et al., 1997; Gerber and Sudhof, 
2002). High [Ca2 ]i plays a critical role in secretagogue-induced glucagon secretion 
(Pipeleer et al., 1985; Hii and Howell, 1986). Stimulation of pancreatic a-cells with 
secretagogues such as AVP results in a rise in [Ca2+], due to Ca2 release from endoplasmic 
reticulum and G a2 influx from the extracellular space (Yibchok-anun et al., 2000). Many 
effects of Ca2* are mediated through Ca2+-binding proteins such as calmodulin (CaM). The 
93 
effects of Ca"/CaM may be mediated by CaMK II (Hanson and Schulman 1992; Miyamoto 
et al., 1997; Easom, 1999). The CaMK II may play a partial role in glucagon release since 
the selective inhibitor, KN93, partially blocked AVP-induced glucagon release and 
forskolin/A VP-induced glucagon release. How Ca2^ increase regulates the complex series of 
steps that results in neurotransmitter/hormonal release remains largely unknown, but SNARE 
complex proteins and synaptotagmin play important roles in regulation of this process (for 
review see Sudhof, 1995; Hilfiker et al., 1999; Gerber and Sudhof, 2002). 
Previous studies showed that Ca2* mobilization and IP3 accumulation induced by 
ethanol and vasopressin in rat hepatocytes were potentiated by cpt-cAMP (Higashi et al., 
1996). Agents that increase cAMP levels have no significant effects on basal inositol 
phosphate synthesis but enhance the effect of AVP-induced IP3 accumulation (Pittner and 
Fain, 1989a,b). IP3 induces Ca2* release from the endoplasmic reticulum, therefore any 
increase in IP3 formation will be detected by an increase in [Ca2*]j. In addition, 30% of the 
total stimulatory effect of cAMP enhanced glucagon release from pancreatic a-cells was by 
enhancement of Ca2* influx through L-type channels (Gromada et al., 1997). We determined 
if in our system cAMP also mediated its effect through further increase in [Ca2*],. In contrast 
to the above studies, our findings suggested that the enhancement effect of cAMP/PKA on 
AVP-induced glucagon release is not mediated through the modulation of [Ca2*]j and it 
occurs at a site distal to the elevation of [Ca2*],. 
How can activation of PKA (e.g., in response to forskolin) enhances exocytosis? 
PKA must do more than simply change the Ca2* affinity in the fusion machinery (Ammala et 
al., 1993). The most straightforward explanation for these results is that phosphorylation by 
PKA increases the number of granules available for Ca2*-regulated fusion. The fact that 
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glucagon release was prolonged with forskolin treatment in the perfused rat pancreas and 
from InRlG9 cells suggests that PKA promotes the mobilization of secretory granules from 
RP to RRP. Styryl dyes, which were originally developed as membrane potential sensors, 
have become useful tools in the study of exocytosis, endocytosis and synaptic vesicle 
recycling (Betz et al, 1996; Cochilla et al, 1999). This is due to their ability to reversibly 
stain membranes, their inability to penetrate membranes, and their fluorescence (Betz et al, 
1996; Cochilla et al, 1999). FM 1-43 is one of the most extensively used styryl dyes to study 
secretory activity (Cochilla et al, 1999). It is non-fluorescent in aqueous solution, but 
becomes fluorescent and its quantum yield increases by ~ 350 times when incorporated into 
the plasma membrane (Betz et al, 1992). Therefore, the fluorescence intensity is proportional 
to the amount of membrane exposed to FM 1-43. Upon stimulation, exocytosis causes the 
vesicular membrane to fuse with the plasma membrane, and the dye binds to the exocytosing 
membrane resulting in an increase of fluorescence intensity. Therefore, the fluorescence 
intensity can be used as an index for the size of RRP (Cochilla et al., 1999; Cousin and 
Robinson, 1999; Kuromi and Kidokoro, 1998; 2000, Sudhof, 2000). The advantage of this 
imaging method as an indicator of exocytosis, over traditional methods which measure 
glucagon release, is that it enables measurement of exocytosis from individual cells with high 
temporal resolution. Using this method we demonstrated that the combination of AVP and 
forskolin induced more increase in fluorescent intensity (Fig. 16), which reflects an increase 
in the number of secretory granule membranes fused with the plasma membrane and 
therefore an increase in the size of RRP. 
One possible mechanism for the recruitment of the secretory granules from RP is the 
release of granules from the actin-based cytoskeleton induced by phosphorylation of 
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synapsin I (Greengard et al., 1993; Brodin et al., 1997; Benfenati et al., 1999; Hosaka et al., 
1999). In pancreatic (3- and a-cells, the actin network beneath the plasma membrane may 
prevent the interaction between secretory granules and plasma membranes (Orci, 1982). By 
analogy with neuronal cells, synapsin I in a-cells cells may function as a linker between 
glucagon secretory granules and the cytoskeletal network. Synapsin I is found in glucagon-
expressing a-cells including InRlG9 cells (Matsumoto et al., 1999) and is phosphorylated at 
its N-terminus by CaMK H and PKA (Sudhof, 1995). Until now, neither the function of 
synapsin I phosphorylation in a-cells nor the significance of phosphorylation by PKA is clear 
in pancreatic a-cells. The present study showed that synapsin I is likely involved in 
forskolin/A VP-induced glucagon release as well as in the mobilization of secretory granules 
from RP to refill RRP. Pretreatment with antisynapsin I antibody abolished the effect of 
forskolin/AVP-induced glucagon release but not glucagon release in the control, AVP, or 
forskolin groups. These findings were confirmed by the exocytosis experiments using FM1-
43 loaded cells. 
In this study, we present the first work demonstrating the effects of cAMP/PKA on 
single exocytotic events and the involvement of synapsin I on glucagon-secreting cells 
(InRlG9). Our findings suggested that cAMP, acting through PKA, increases the number of 
secretory granules in RRP by mobilization of granules from RP, an action mediated by 
Synapsin I (Fig. 19). In order for exocytosis to continue during extensive stimulation, RRP 
must be supplied with secretory granules from RP. Agents that increase intracellular cAMP 
concentrations cause sustained exocytosis (Eddlestone et al., 1985; Hill et al., 1987; Gills and 
Misler, 1993) and have been used in combination with secretagogues to augment exocytosis 
(Wiedenkeller and Sharp, 1983; Henquin 1985; Wang et al., 1993) This effect may be due to 
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an increase in the size of RRP as indicated in this study and others (Renstrom et al., 1997; 
Gromada et al., 1997). Because of the similarities between glucagon granules and other 
neuroendocrine cells such as pancreatic (3-cells, chromaffin cells, pituitary somatotrophs, 
pituitary melanotrophs and lactotrophs, it is probable that our results that elevated 
intracellular cAMP concentrations can modulate the size of RRP can be extrapolated to these 
endocrine cells. 
Diabetic patients have elevated levels of plasma AVP (Grimaldi et al., 1988; Tinder 
et al., 1994) and the a-cells from diabetic subject may exhibit an exaggerated response to 
AVP (our unpublished data). Therefore, our present findings that elevation of cAMP 
concentrations enhances AVP-induced glucagon may partially account for the clinical 
observations that hypersecretion of glucagon aggravates the hyperglycemia associated with 
type 2 diabetes (Unger and Orci 1995; Dinnen et al., 1995). 
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Fig 1. Effects of forskolin on AVP-induced glucagon release from the perfused rat pancreas. 
In these experiments, a 20-min equilibration period preceded time 0. After a baseline period 
of 12 min, AVP (30 pM), forskolin (10 |iM), or the combination of forskolin and AVP were 
administered for 30 min (heavy line), followed by a 6 min washout period. Values are the 
mean ± SE (n = 4). Basal control (•); forskolin (•); AVP (•); and the combination of 
forskolin and AVP (•). Range of baseline glucagon concentrations of effluents was 32-70 
pg/ml. 
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Fig 2. Effects of forskolin on AVP-induced glucagon release in the perifusion of InRlG9 
cells. In these experiments, a 15-min equilibration period preceded time 0. After a baseline 
period of 10 min, AVP (100 nM), forskolin (10 jiM), or the combination of forskolin and 
AVP were administered for 30 min (heavy line), followed by a 10 min washout period. 
Values are the mean ± SE (n = 3). Basal control (•); forskolin (A); AVP (•); and the 
combination of forskolin and AVP (•). Range of baseline glucagon concentrations of 
effluents was 25-72 pg/ml. 
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Fig 3. Effects of forskolin (F) (10 |iM) and IB MX (100 gM) on AVP (100 nM)-induced 
glucagon release in InRlG9 cells. Static incubation was performed for 15 min to determine 
glucagon release. Values are mean ± SE (n = 4 cultures with triplicates). *P < .05 vs. 
Control; * P< .05 vs. AVP alone. 
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Fig 4. Effects of forskolin (F) (F 10= 10 |xM, Fl= 1 fxM, or F0.1= 0.1 |iM) on AVP (100 
nM)-induced glucagon release in InRlG9 cells. Static incubation was performed for 15 min 
to determine glucagon release. Values are mean ± SE (n = 4 cultures with triplicates). *P < 
.05 vs. Control; # P< .05 vs. AVP alone. 
107 
Control AVP F+AVP Control AVP F+AVP 
Fig 5. Effects of SQ-22536 (SQ) (100 gM) on forskolin (F)-(10 nM), AVP- (lOOnM) and 
the combination of forskolin and AVP-induced glucagons release in InRlG9 cells. SQ was 
given 30 min before the administration of AVP. Static incubation was performed for 15 min 
to determine glucagon release. Values are mean ± SE (n = 4 cultures with triplicates). *P < 
.05 vs. Control; 8 P< .05 vs. AVP alone. 
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Fig 6. Effects of forskolin (F) (10 pM) and the inactive analog of forskolin, 1,9 
dideoxyforskolin (F-analog) (10 gM) on AVP (100 nM)-induced glucagon release in InRlG9 
cells. Static incubation was performed for 15 min to determine glucagon release. Values are 
mean ± SE (n = 4 cultures with triplicates). *P < .05 vs. Control; * P< .05 vs. AVP alone. 
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Fig 7. Effects of H-89 (1 fiM), a selective inhibitor of PKA, on forskolin (F) (1 gM)/ AVP 
(100 nM) induced glucagon release in InRlG9 cells. H-89 was pretreated for 24 h. Static 
incubation was performed for 15 min to determine glucagon release. Values are mean ± SE 
(n = 4 cultures with triplicates). *P < .05 vs. Control; * P< .05 vs. AVP alone. 
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Fig 8. Effects of forskolin (F) (10 gM) and the inactive analog of forskolin, 1,9 
dideoxyforskolin (F-analog) (10 gM) and AVP (lOOnM) on cAMP production in InRlG9 
cells. Static incubation was performed for 15 min to determine cAMP levels. Values are 
mean ± SE (n = 3 cultures with quadruplicates). *P < .05 vs. control. 
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Fig 9. Effects of IBMX (100 fiM) on cAMP production in InRlG9 cells. Static incubation 
was performed for 15 min to determine cAMP levels. Values are mean ± SE (n = 3 cultures 
with quadruplicates). *P < .05 vs. control. 
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Fig 10. Effects of SQ-22536 (SQ) (100 pM) on forskolin (10 |xM)-induced cAMP 
production in InRlG9 cells. SQ was given 30 min before the administration of forskolin. 
Static incubation was performed for 15 min to determine cAMP levels. Values are mean ± 
SE (n = 3 cultures with quadruplicates). *P < .05 vs. Control. 
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Fig 11. Effects of forskolin (10 pM) on A VP (100 nM)-induced increase in [Ca2+]j. 
Forskolin failed to further increase A VP-induced [Ca2-^,. Traces are representative of 3 
experiments. 
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Control A VP F F+AVP Control AVP F F+AVP 
Fig 12. Effects of forskolin (F) (10 |iM)/AVP (100 nM)-induced glucagon release in Ca2+-
containing and Ca2-&ee KRB. Static incubation was performed for 15 min to determine 
glucagon release. Values are mean ± SE (n=4 cultures with triplicates). *P < .05 vs. Control 
in Ca2^-containing media;* P< .05 vs. AVP alone. 
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Fig 13. Effects of IBMX (100 ^iM)/AVP (100 nM)-induced glucagon release in Ca" -
containing and Ca:*-free KRB. Static incubation was performed for 15 min to determine 
glucagon release. Values are mean ± SE (n=4 cultures with triplicates). *P < .05 vs. Control 
in Ca"-containing media; * P< .05 vs. AVP alone. 
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Fig 14. Effects of forskolin (F) (10 (iM)/AVP (100 nM)-induced glucagon release in Ca" -
containing media and under deprived Ca"-condition (25 (xM BAPTA-AM in Ca2+-containing 
media). BAPTA-AM in Ca'^-containing media was given 30 min before the administration 
of AVP. Static incubation was performed for 15 min to determine glucagon release. Values 
are mean ± SE (n=4 cultures with triplicates). *P < .05 vs. control without BAPTA-AM; * 
P< .05 vs. AVP alone. 
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Fig 15. Effects of KN-93 (1 |oM), a selective CaM kinase II inhibitor, on forskolin (F) (10 
(iM)/AVP (100 nM)-induced glucagon release. KN-93 was given 30 min before the 
administration of AVP. Static incubation was performed for 15 min to determine glucagon 
release. Values are mean ± SE (n=4 cultures with triplicates). *P < .05 AVP vs. AVP in 
KN-93; * P< .05 F+AVP vs. F+AVP in KN-93 alone. 
Fig 16. Effects of forskolin and AVP on FM1-43 fluorescence intensities in InRlG9 cells. 
A) Forskolin (F) (10 fiM) enhanced AVP (100 nM)-induced fluorescence intensities. FM1-
43 loading, fluorescent imaging and quantitative analysis of fluorescence intensities are 
described in the Materials and Methods. Values are mean ± SE (n= at least 200 individual 
cells for each treatment group). *P < .05 vs. control; 8 P< .05 vs. AVP alone. B) 
Fluorescence images of representative cells from (A) loaded by FM 1-43 in control, forskolin 
(F), AVP, and the combination of AVP and forskolin (F + AVP). 
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Fig 17. Effects of antisynapsin I antibody on forskolin (F) (10 (iM)/AVP (100 nM)-induced 
glucagon release. Antisynapsin I was given 4 h before the administration of the treatment as 
described in the Materials and Methods. Static incubation was performed for 15 min to 
determine glucagon release. Values are mean ± SE (n=4 cultures with triplicates). *P < .05 
vs. control without antisyapsin antibody I, * P< .05 vs. AVP alone. 
Fig 18. Effect of forskolin and AVP on FM1-43 fluorescence intensities in InRlG9 cells. A) 
Antisyanpsin I antibody (AB) abolished the effect of forskolin (F) (10 fiM) enhancement on 
AVP (100 nM)- induced fluorescence intensities. FM 1-43 loading, fluorescent imaging and 
quantitative analysis of fluorescence intensities are described in the Materials and Methods. 
Values are mean ± SE (n= at least 200 individual cells for each treatment group). *P < .05 
vs. control; * P< .05 vs. AVP alone. B) Fluorescence images of representative cells from (A) 
loaded by FM 1-43 in control, forskolin (F), AVP, and the combination of forskolin and AVP 
(F+AVP) and in groups that were pretreated with antisyanpsin I antibody control-AB , 
forskolin-AB, AVP-AB , and the combination of forskolin-AB and AVP-AB (F+AVP-AB). 
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Fig 19. Mechanism of cAMP dependent protein kinase A (PKA) enhanced arginine 
vasopressin (AVP)-induced glucagon release. PKA may enhance A VP-induced glucagon 
release by mobilization of secretory granules from the reserve pool (RP) to the readily 
releasable pool (RRP), an action mediated through synapsin I. 
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CHAPTER IV. GENERAL CONCLUSIONS 
This chapter contains the discussion and the conclusions obtained from the present 
studies that may be found in the Discussion section of each chapter. In addition, it consists 
of the possible physiological and clinical implications that are related to our findings. Also, 
it includes suggestions for the further studies. 
Glucose-Dependency of AVP 
In the present study, AVP evoked both the release of insulin and glucagon from the 
perfused rat pancreas in a glucose concentration-dependent manner. Our findings suggest that 
the higher the glucose concentration, the greater the enhancement of AVP-induced insulin 
release. In contrast, the lower the glucose, the greater the enhancement of A VP-induced 
glucagon release. In the pancreatic mouse islets, AVP (100 nmol/L) in the presence of 0, 3, 
or 7 mmol/L glucose failed to induce insulin release (Gao et al., 1992). These authors 
concluded that AVP is not an initiator of insulin release but only enhances glucose-induced 
insulin release. In contrast, our study demonstrated that lower concentration of AVP (300 
pmol/L) not only enhanced glucose-induced insulin release, but also initiated insulin release 
in the basal level of glucose (5.5 mmol/L). 
Our findings suggest that AVP has a much greater impact on glucagon than insulin 
release since AVP (30 pmol/L) increased glucagon but not insulin release. These findings 
suggest that a-cells are more sensitive to AVP than p-cells in hormone release. These 
findings are consistent with those obtained from the perfused rat pancreas (Dunning et al., 
1984a) and isolated rat islets (Dunning et al., 1984b) and are different from those obtained 
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from the mouse islets (Gao et al., 1992). In addition, our findings support the notion that 
AVP has a direct stimulatory effect on glucagon release in a-cells. 
During hypoglycemic stress, glucagon release increases and insulin release decreases. 
Increased glucagon release is the main counterregulatory factor in the recovery of 
hypoglycemia (Gerich et al, 1979; Cryer, 1981). However, the mechanism underlying 
hypoglycemia-induced glucagon release is uncertain. A number of studies suggest that the 
increase in release is due to the activation of autonomic nervous system (Havel and 
Taborsky, 1989; Havel and Valverde, 1996; Havel et al., 1996). In contrast, our results 
suggested that the low glucose level directly increases glucagon release, because these 
experiments were performed in isolated perfused pancreas where there was no input from the 
autonomic nervous system. These findings are consistent with those found in the isolated 
islets (Oliver et al., 1976) and perfused pancreata (Weir et al., 1974). 
In conclusion, the results from this study suggest that hypoglycemia directly 
increases glucagon and decreases insulin release. AVP may increase insulin and glucagon 
release by a direct action on (3- and a-cells, respectively. These increases are glucose-
dependent; the higher the glucose concentration, the greater the enhancement of AVP 
induced insulin release. In contrast, the lower the glucose concentration, the greater the 
enhancement of AVP induced glucagon release. AVP not only may enhance glucose-
induced insulin release, but may also initiate insulin release, a-cells are much more sensitive 
to AVP than (3-celIs in hormone release. Our findings indicate that AVP may physiologically 
increase glucagon release, since AVP increased glucagon release at similar plasma 
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concentrations of AVP (< 30 pmol/L) (Thibonnier, 1992), while failed to increase insulin 
release at these concentrations. 
The mechanisms underlying the glucose enhancement of A VP-induced insulin and 
glucagon releases are not known. Further studies are needed to investigate the mechanisms 
underlying this enhancement. 
cAMP/PKA Enhances A VP-Induced Glucagon Release 
In this study, we demonstrated that cAMP/PKA enhance A VP-induced glucagon 
release from the perfused rat pancreas and InRlG9 cells. Thereafter, we investigated the 
intracellular molecular mechanism of cAMP/PKA-dependent enhancement of A VP-induced 
glucagon release, particularly at the level of exocytosis. 
The effect of cAMP/PKA on A VP-induced glucagon release is Ca"-dependent. This 
is expected since most of the exocytotic fusion is Ca2+-dependent. Granule fusion, per se, 
occurs independently of protein kinase involvement and is thought to be mediated by the 
direct action of Ca2* influx through Ca27phospholipid binding protein synaptotagmin (Lang 
et al.. 1997; Gerber and Sudhof, 2002). High [Ca2"], plays a critical role in secretagogue-
induced glucagon secretion (Pipeleers et al., 1985; Hii and Howell, 1986). Stimulation of 
pancreatic a-cells with secretagogues such as AVP results in a rise in [Ca2*], due to Ca2* 
release from endoplasmic reticulum and Ca2* influx from the extracellular space (Yibchok-
anun et al., 2000). Many effects of Ca2* are mediated through Ca2-binding proteins such as 
calmodulin (CaM). The effects of Ca2/CaM may be mediated by CaMK II (Hanson and 
Schulman 1992; Miyamoto et al., 1997; Easom, 1999). Our findings suggest that CaMK II 
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may play a partial role in AVP- and forskolin/A VP-induced glucagon release. Although how 
Ca2* increase regulates the complex series of steps that results in neurotransmitter/ hormonal 
release remains largely unknown, SNARE complex proteins and synaptotagmin play 
important roles in regulation of this process (for review see Sudhof, 1995; Hilfiker et al., 
1999; Gerber and Sudhof, 2002). Synaptotagmin is an integral Ca"-binding protein of 
synaptic vesicle membranes, and binding of Ca2+ to synaptotagmin is necessary for fusion of 
the membranes of secretory granules and the plasma membrane (Gerber and Sudhof, 2002). 
Gerber and Sudhof (2002) have proposed out a model for the molecular machinery that 
mediates membrane fusion during exocytosis. However, much remains to be clarified in this 
cycle including the precise function of certain exocytotic proteins, the validation of the 
hypothesis that the core complex formation from SNAREs drives fusion, and how Ca2* 
triggers exocytosis. 
The next question is how activation of PKA (e.g., in response to forskolin) enhances 
A VP-induced glucagon release. PKA must do more than simply changing the Ca2* affinity 
in the fusion machin ary (Ammala et al., 1993) or further enhanceing A VP-induced [Ca2*], (as 
shown in this study). The most straightforward explanation for these results is that 
phosphorylation by PKA increases the number of granules available for Ca2~-regulated 
fusion. The fact that glucagon release was prolonged with forskolin treatment in the perfused 
rat pancreas and from InRlG9 cells led us to hypothesize that PKA promotes the 
mobilization of secretory granules from RP to RRP. Styryl dyes, which were originally 
developed as membrane potential sensors, have become useful tools in the study of 
exocytosis, endocytosis and synaptic vesicle recycling (Betz et al, 1996; Cochilla et al, 
1999). The advantage of this imaging method as an indicator of exocytosis, over traditional 
128 
methods measuring glucagon release, is that it enables measurement of exocytosis from 
individual cells with high temporal resolution. Using this method we demonstrated that 
c AMP/PKA, increases the number of secretory granules in RRP. One limitation of this 
method is that in order to detect the fluorescent intensity, FM 1-43 dye must bind to the 
exocytosing membrane as secretory granules fuse with plasma membrane during exocytosis. 
Therefore, an agent that increases the size of RRP can not be detected with this method 
unless it is used in combination with a secretagogue that induces exocytosis. Thus, the FM1-
43 method provides indirect evidence to measure the size of RRP. The use of electron 
microscopy provides a direct determination for the increase in the size of RRP (Augustin et 
al., 1999; Neale et al., 1999). 
How are the secretory granules released from RP to RRP? One possible mechanism 
for the recruitment of the secretory granules from RP is the release of granules from the 
actin-based cytoskeleton induced by phosphorylation of synapsin I (Greengard et al., 1993; 
Brodin et al., 1997; Benfenati et al., 1999; Hosaka et al., 1999). By analogy with neuronal 
cells, synapsin I in a-cells cells may function as a linker between glucagon secretory granules 
and the cytoskeletal network. Synapsin I is found in glucagon-expressing a-cells including 
InRlG9 cells (Matsumoto et al., 1999) and is phosphorylated at its N-terminus by CaMK II 
and PKA (Sudhof, 1995). Until this present study, neither the function of synapsin I 
phosphorylation in a-cells nor the significance of phosphorylation by PKA in pancreatic a-
cells was clear. The present study showed that synapsin I is likely involved in 
forskolin/AVP-induced glucagon release as well as in the mobilization of secretory granules 
from RP to refill RRP. 
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Pathophysiological Significance 
In this study, we present the first work demonstrating the effects of cAMP/PKA on 
single exocytotic events and the involvement of synapsin I on glucagon-secreting cells 
(InRlG9). Our findings suggested that cAMP, acting through PKA, increases the number of 
secretory granules in RRP by mobilization of granules from RP, an action mediated by 
synapsin I. In order for exocytosis to continue during extensive stimulation, RRP must be 
supplied with secretory granules from RP. Agents that increase intracellular cAMP 
concentrations cause sustained exocytosis (Eddlestone et al., 1985; Hill et al., 1987; Gills and 
Misler, 1993) and have been used in combination with secretagogues to augment exocytosis 
(Henquin 1985; Sharp et al., 1993; Wang et al., 1993). This effect is due to an increase in the 
size of RRP as indicated in this study and others (Renstrom et al., 1997; Gromada et al., 
1997). Because of the similarities between glucagon granules and other secretory granules 
in neuroendocrine cells such as pancreatic (3-cells, chromaffin cells, pituitary somatotrophs, 
pituitary melanotrophs and lactotrophs, it is probable that our results can be extrapolated to 
these endocrine cells, and suggest that elevated intracellular cAMP concentrations can 
modulate the size of RRP. 
Diabetic patients have elevated levels of plasma AVP (Grimaldi et al., 1988; Tinder 
et al., 1994) and the a-cells from diabetic subjects may exhibit an exaggerated response to 
AVP (our unpublished data). Therefore, our present findings that elevation of cAMP 
concentrations enhances A VP-induced glucagon may partially account for the clinical 
observations that hypersecretion of glucagon aggravates the hyperglycemia associated with 
type 2 diabetes (Unger and Orci 1995; Dinnen et al., 1995). AVP may aggravate 
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hyperglycemia in diabetic patients by increasing glucagon secretion. It is possible that the 
use of Vib receptor antagonists may decrease glucagon release in these patients. Further 
work is needed to prove or disprove this hypothesis. 
Future studies 
Several lines of evidence suggest that phosphorylation of exocytotic proteins play a 
major role in modulating neurotransmitter/hormonal release. Although, the precise 
downstream targets of PKA are currently unknown, several intracellular regulatory proteins 
have been shown to be substrates for PKA in vitro. These include rabphilin-3A (Lonart et 
al., 1998), synapsin (Sudhof, 1995), syntaxin (Trudeau et al., 1998) and SNAP-25 (Foster et 
al., 1998). Thus, it is likely that the modulation of glucagon release produced by the 
activated PKA could occur through a direct phosphorylation of one or more of these 
exocytotic proteins. In addition, A VP-induced glucagon release is mediated largely by a 
Ca2*-dependent pathway (Yibchok-anun et al., 2000). It is well known that Ca2* activates 
CaMK II, which may lead to phosphorylation of a set of exocytotic proteins including 
rabphilin-3A (Fykse et al., 1995), synaptotagmin (Popoli, 1993), syntaxin (Trudeau et al., 
1998) and SNAP-25 (Foster et al., 1998). 
Although, both PKA and CaMKII may phosphorylate the mentioned above 
exocytotic proteins, the information is still largely unknown and controversial. First, most of 
the studies were performed in the cell-free system using the catalytic subunit of PKA and 
purified CaMKII to demonstrate the phosphorylation by these kinases. This might not be the 
case if these studies were performed in cells under physiological conditions. For example, in 
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intact cells CaMKII but not PKA phosphorylated rabphilin-3A (Fykse, 1998), whereas in 
cell-free system both PKA and CaMKII phosphorylated rabphilin-3A (Fykse, 1995; Lonart et 
al., 1998). Second, there are contradictory findings between studies. For example, syntaxin 
was phosphorylated by PKA in one study (Foster et al., 1998) but not in another (Risinger 
and Bennett, 1999). SNAP-25 was phosphorylated by PKA in one study (Risinger and 
Bennett, 1999) but not in another one (Foster et al., 1998). Third, these studies did not 
compare the magnitude of protein phosphorylation between PKA and CaMKII. 
Although, the CaMK H inhibitor, KN93, reduced AVP- and forskolin/A VP-induced 
glucagon release, the reduction was small. In addition, we recently found that CaMK II 
antibody failed to reduce the effect of AVP or AVP/forskolin on glucagon release 
(unpublished data). This suggests that CaMK II may only play a minor role in glucagon 
release and the increase in Ca2* may directly activate other exocytotic proteins. Investigation 
of the potential phosphorylation of the above-mentioned proteins by PKA and CaMK II and 
the magnitude of the phosphorylation could provide better understanding of the efficacy of 
downstream steps in the exocytotic process. 
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